



Oliver, C. M., Warnakulasuriya, S., McGuckin, D., Singleton, G., Vallance, A. E., & Moonesinghe, S. R. (2022). Delivery of drinking, eating and mobilising (DrEaMing) and its association with length of hospital stay after major noncardiac surgery: observational cohort study. *British Journal of Anaesthesia*, *129*(1), 114-126. https://doi.org/10.1016/j.bja.2022.03.021

Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1016/j.bja.2022.03.021

Link to publication record in Explore Bristol Research PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at https://doi.org/10.1016/j.bja.2022.03.021. Please refer to any applicable terms of use of the publisher

University of Bristol - Explore Bristol Research General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/

British Journal of Anaesthesia, 129 (1): 114-126 (2022)

doi: 10.1016/j.bja.2022.03.021 Advance Access Publication Date: 12 May 2022 Quality and Patient Safety

Delivery of drinking, eating and mobilising (DrEaMing) and its association with length of hospital stay after major noncardiac surgery: observational cohort study *

Charles M. Oliver^{1,2}, Samantha Warnakulasuriya^{1,2,3}, Dermot McGuckin^{1,2,3}, Georgina Singleton^{1,2,3}, Peter Martin⁴, Cristel Santos³, James Bedford³, Duncan Wagstaff^{1,3}, Arun Sahni³, David Gilhooly^{1,2,3}, Jonathan Wilson⁵, Kylie Edwards^{1,3}, Rachel Baumber^{1,3,6}, Cecilia Vindrola-Padros^{1,3}, Jenny Dorey⁷, Irene Leeman⁷, Hannah Boyd-Carson^{8,9}, Ravi Vohra^{8,10}, Pritam Singh¹¹, Matthew Bedford¹², Abigail Vallance¹³, Giuseppe Aresu¹⁴, Olga Tucker¹², Michael Swart¹⁵, Monty G. Mythen¹⁶, PQIP project delivery team[†], Suneetha R. Moonesinghe^{1,2,3,16,*}, and for the PQIP collaborative

¹Centre for Perioperative Medicine, Research Department for Targeted Intervention, Division of Surgery and Interventional Science, University College London, London, UK, ²Department of Anaesthesia and Perioperative Medicine, University College London Hospitals, London, UK, ³Health Services Research Centre, National Institute for Academic Anaesthesia, Royal College of Anaesthetists, London, UK, ⁴Department for Applied Health Research, University College London, London, UK, ⁵York University Hospitals, York, UK, ⁶Royal National Orthopaedic Hospital, Stanmore, UK, ⁷Royal College of Anaesthetists, London, UK, ⁸East Midlands Surgical Academic Network, Queen's Medical Centre, Nottingham, UK, ⁹Department of General Surgery, Derby Teaching Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, UK, ¹⁰Trent Oesophago-Gastric Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK, ¹¹Regional Oesophago-Gastric Unit, Royal Surrey County Hospital, Guildford, Surrey, UK, ¹²Division of Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, ¹³Bristol Medical School, University of Bristol, Bristol, UK, ¹⁴Department of Thoracic Surgery, Royal Papworth NHS Foundation Trust, Cambridge, UK, ¹⁵Department of Anaesthesia and Perioperative Medicine, Torbay Hospital, Torquay, UK and ¹⁶University College London Hospitals National Institute of Health Research Biomedical Research Centre, London, UK

*Corresponding author. E-mail: ramani.moonesinghe@nhs.net

[†]See supplementary material for list.

This article is accompanied by an editorial: Postoperative recovery: DrEaMing as a wake-up call? by Henrik Kehlet, Br J Anaesth 2022:129:1–3, doi: 10.1016/j.bja.2022.04.005

*The findings of this study were presented in part at Evidence Based Perioperative Medicine (EBPOM), London, 2021.

Abstract

Background: Enhanced recovery pathways are associated with improved postoperative outcomes. However, as enhanced recovery pathways have become more complex and varied, compliance has reduced. The 'DrEaMing' bundle reprioritises early postoperative delivery of drinking, eating, and mobilising. We investigated relationships between DrEaMing compliance, postoperative hospital length of stay (LOS), and complications in a prospective multicentre major surgical cohort.

Methods: We interrogated the UK Perioperative Quality Improvement Programme dataset. Analyses were conducted in four stages. In an exploratory cohort, we identified independent predictors of DrEaMing. We quantified the association between delivery of DrEaMing (and its component variables) and prolonged LOS in a homogenous colorectal subgroup

Received: 30 November 2021; Accepted: 24 March 2022

© 2022 The Authors. Published by Elsevier Ltd on behalf of British Journal of Anaesthesia. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).

For Permissions, please email: permissions@elsevier.com

and assessed generalisability in multispecialty patients. Finally, LOS and complications were compared across hospitals, stratified by DrEaMing compliance.

Results: The exploratory cohort comprised 22 218 records, the colorectal subgroup 7230, and the multispecialty subgroup 5713. DrEaMing compliance was 59% (13 112 patients), 60% (4341 patients), and 60% (3421), respectively, but varied substantially between hospitals. Delivery of DrEaMing predicted reduced odds of prolonged LOS in colorectal (odds ratio 0.51 [0.43–0.59], P<0.001) and multispecialty cohorts (odds ratio 0.47 [0.41–0.53], P<0.001). At the hospital level, complications were not the primary determinant of LOS after colorectal surgery, but consistent delivery of DrEaMing was associated with significantly shorter LOS.

Conclusions: Delivery of bundled and unbundled DrEaMing was associated with substantial reductions in postoperative LOS, independent of the effects of confounder variables. Consistency of process delivery, and not complications, predicted shorter hospital-level length of stay. DrEaMing may be adopted by perioperative health systems as a quality metric to support improved patient outcomes and reduced hospital length of stay.

Keywords: enhanced recovery; patient-centred outcomes; perioperative; quality improvement; quality metric; shared decision-making; surgical outcomes

Editor's key points

- Enhanced recovery pathways have been widely adopted but implementation can be difficult and high compliance variable.
- A simplified 'bundle' approach has been proposed, where the aim is to support patients to DRink free fluids, EAt a soft diet and Mobilise with the maximum assistance of one person (DrEaMing) within 24 h of surgery ending.
- This study evaluated the relationship between DrEaMing and postoperative length of stay in a national cohort of patients undergoing major elective surgery.
- In the overall cohort of 22,218 participants, and in two sub-groups, DrEaMing compliance was around 60% and associated with significantly reduced length of stay, independent of confounders including patient and hospital level factors. DrEaMing was also associated a lower risk of later postoperative complications.
- In a homogenous sub-group of patients undergoing one of four colorectal procedures (n = 7230), the quintile of hospitals with the highest DrEaMing compliance had a 2-day shorter median length of stay than the quintile with the lowest DrEaMing compliance.
- DrEaMing fulfils many of the criteria of an ideal care bundle and improvement target and may be adopted as a quality metric by perioperative health systems.

Enhanced recovery is proposed to reduce the stress response and accelerate recovery from surgery.¹ The rationale is the prevention of iatrogenic harm from fluid imbalance, avoidance of the deleterious effects of immobility, and promotion of early return of normal homeostasis, by consistently delivering core perioperative processes.² There are limited data indicating cost savings, both to healthcare providers and the wider society,³ associated with implementation of enhanced recovery programmes.⁴ Original enhanced recovery pathways (ERPs) comprised four processes, prioritising early mobilisation and resumption of oral diet.¹ However, ERPs have since become substantially more complex, with between 12 and 20 elements depending on surgery type.⁴ However, although close compliance is associated with improved patient outcomes,⁵ there is widespread evidence that not only the implementation, but also sustained use of ERPs is challenging.⁴ Other key issues include: inadequate or conflicting evidence on the effectiveness of individual processes, resulting in debate over which to mandate and in which subpopulations^{6–9}; and the challenges arising from the shared and often overlapping responsibility for the delivery of ERP processes between multidisciplinary teams across the perioperative period.¹⁰.¹¹

Care bundles are sets of processes which, when delivered together, have been shown to be associated with improved outcomes across a variety of healthcare contexts.¹² They should comprise no more than three to five component processes, each of which should have robust supporting evidence of efficacy and be supported by a clinical consensus.^{13,14} Returning to the core components of ERPs, the 'DrEaMing' bundle was developed to promote the delivery of early drinking, eating, and mobilising within 24 h of surgery.¹⁵ DrEaMing is an attractive process bundle, since both its components and purpose are intuitive, components are not controversial for most procedures, and it fulfils the above requirements for care bundles.¹³ However, few studies have specifically evaluated the impact of DrEaMing on postoperative outcomes, or whether delivery of this bundle improves overall ERP compliance when nested within one.¹⁶ We hypothesise that, as both a process and outcome, DrEaMing is associated with uncomplicated postoperative recovery and discharge from hospital, and therefore reduced length of postoperative stay. This study therefore interrogates the relationships between DrEaMing and postoperative length of stay (LOS) and complications in a large prospective multispecialty, multicentre cohort of patients undergoing a representative sample of major surgical procedures.

Methods

The study had three aims: to evaluate the association between delivery of DrEaMing within 24 h of surgery and postoperative LOS; to identify patient and process factors predictive of failure to DrEaM; and to explore the specific confounding effect of postoperative complications on the association between DrEaMing and LOS at hospital level. This manuscript was prepared to comply with STROBE guidelines.¹⁷

Data source and approvals

We analysed data from the UK national Perioperative Quality Improvement Programme (PQIP, www.pqip.org.uk) collected for patients who underwent surgery between 13 December 2016 and February 28, 2020 (cohort start and end dates determined by the study start date, and the date of the COVID-19 pandemic beginning to impact on hospital processes). PQIP is a prospective observational cohort study of a sample of adults (>18 yr on date of surgery) undergoing major, planned noncardiac surgery in UK NHS hospitals.^{18–20} The full list of eligible operations is available on the PQIP website. Local research teams recruit five eligible patients per specialty at their site each week. Case-mix, process, and outcome data are collected locally and submitted electronically into the web-based study database. PQIP was approved by the Health Research Authority (London-Surrey Research Ethics Committee REC reference number: 16/LO/1827).

Inclusions

Records were eligible for inclusion if: the patient survived to hospital discharge (Supplementary Fig 1), to exclude misleading short LOS in decedents; data items required to calculate LOS were recorded; LOS exceeded 24 h (to include only major procedures), and no component of DrEaMing was expressly contraindicated based on the surgical procedure performed (Supplementary Table S1). This list of procedures was ratified by expert clinicians. Resulting records comprised an exploratory cohort, within which colorectal and multispecialty subgroups were identified. Colorectal procedures were selected on the grounds of the substantial existing enhanced recovery literature and high volumes of submitted cases to PQIP. Records were eligible for inclusion in the colorectal subgroup if the participant had undergone one of the following four procedures: anterior resection; right hemicolectomy with anastomosis; excision of sigmoid colon; or left hemicolectomy with anastomosis. Records were eligible for inclusion in the multispecialty cohort by surgical procedure, if at least 400 eligible cases were submitted by a minimum of 10 participating hospitals.

Variable definitions

The primary variable of interest was the composite of drinking, eating, and mobilising (DrEaMing) which is recorded 24 h after surgery by PQIP. DrEaMing is defined by PQIP as drinking (tolerating free fluids within 24 h after completion of surgery), eating (restarted and tolerated at least oral soft diet within 24 h after completion of surgery), and mobilising (mobilised from bed to chair with maximum assistance of one within 24 h after completion of surgery); full definitions are reported in Supplementary Table S2.²¹ Secondary variables of interest were the composite DrEaMing+ (DrEaMing plus the cessation of i.v. fluid administration) within 24 h, and individual DrEaMing+ components. The primary outcome was prolonged postoperative LOS, defined as LOS greater than the 75th centile by individual operative procedure. Secondary outcomes were postoperative LOS (days) and major complications (Clavien–Dindo Grade ${\geq}II).^{22}$

PQIP categorises operative urgency as expedited (early, where the condition is not an immediate threat to life, limb, or organ survival) or elective (timing to suit patient, hospital, and staff) using the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) classifications.

Statistical analysis

Overview

We first performed exploratory analyses to identify patient, process, and temporal factors independently associated with achievement of DrEaMing at 24 h in the exploratory cohort. We then performed three analyses in the two subgroups. The first analysis evaluated the relationship between delivery of the DrEaMing bundle and prolonged postoperative LOS in colorectal patients, adjusting for case-mix, other processes, complications, and temporal variation (Supplementary Table S3). The second analysis assessed the generalisability of the relationship between bundle delivery and outcome beyond colorectal procedures, in other high-volume major operations. Finally, to examine the association of hospital-level differences in delivery of DrEaMing on LOS, and to further investigate any confounding effect of complications, LOS distributions and incidences of major complications were assessed across quintiles of hospitals, stratified by the proportion of colorectal patients at hospital level who DrEaMed within 24 h of surgery. Only hospitals that submitted five or more eligible colorectal cases were included in the quintile analysis.

Modelling approach

Data completeness was assessed in eligible records, and sensitivity analyses performed in ineligible records (Supplementary Table S4). In the exploratory cohort, we identified independent predictors of DrEaMing, including patient, surgical, process, and temporal factors, using single and multilevel multiple logistic regression models. Then, case-mix, surgical, process, and temporal covariates, and major postoperative complications were identified for modelling the associations of interest in colorectal and multispecialty subgroups. Criteria for selection of these covariates were putative association with postoperative LOS, applicability across surgical specialties, and >95% completeness in eligible records, regardless of univariate significance (Supplementary Table S3). Specifically, since DrEaMing overlaps enhanced recovery, other enhanced recovery metrics (including carbohydrate loading and postoperative drains) were modelled as confounder variables.²³

Data distributions were assessed, and univariate analyses performed (χ^2 or logistic regression) on prolonged LOS. Categorical variables were re-grouped where classes contained few individuals or events, as reported in the results. Continuous data were Winsorised (1st and 99th centiles), centred about their mean and, in the case of non-linear relationship with prolonged LOS, transformed using a closed-test fractional polynomial approach.²⁴

A mixed-effects multiple logistic regression model was then constructed on prolonged LOS in the colorectal subgroup, with delivery of DrEaMing at 24 h the fixed effect variable of interest, confounder variables as fixed effects, and random intercepts for hospital identifier codes. Odds ratios (ORs) are reported for fixed effects predictors, and the median OR reported to quantify hospital-level influence on LOS.²⁵ The Table 1 Patient characteristics, and perioperative processes and metrics by cohort. Value ranges in parentheses denote inter-quartile ranges and single values percentages.

Primary only 12 015 (54.1) 5118 (70.8) 3281 (57.4) Nodal metastases 3246 (14.6) 859 (11.9) 1030 (18.0) CG findings Normal 17 232 (77.6) 5589 (77.3) 4119 (77.3) AF rate 60-90 beats min ⁻¹ 829 (3.7) 902 (12.5) 731 (12.8) min ⁻¹ /other abnormality Not failure 16 620 (74.8) 5250 (72.6) 4204 (73.6) ardiac signs* No failure 16 620 (74.8) 5250 (72.6) 4204 (73.6) Antihypertensive, digoxin 118 (25.1) 1395 (24.4) 141 (2.0) arear failure (NYHA) class I 18 257 (82.2) 4674 (81.8) II 18 257 (82.2) 5872 (81.2) 4674 (81.8) II or IV 644 (2.9) 200 (2.8) 136 (2.4) yspnoea* None 18 659 (84.1) 6133 (84.8) 4750 (83.1) II or IV 644 (2.9) 200 (2.8) 136 (2.4) yspnoea* None 18 659 (84.1) 6133 (84.8) 4750 (83.1) iot performance 733 (3.3) 218 (3.0) 182 (3.2)	Factor	Class	Main cohort (N=22218)	Colorectal surgery subgroup (N=7230)	Multispecialty subgroup (N=571
ge (yr) 66 (56-73) 67 (56-73) 67 (56-73) Sh physical status 1 23 56 (55.) 405 (56.) 49 (52.) Sh physical status 1 23 64 (50.4) 528 (65.) 407 (55.) Sh physical status 1 13 428 (60.4) 528 (65.) 407 (55.) ody mass index (BMI), kg m ⁻² 4 or 5 23 (12.) 72 (10.4) 53 (19.3) urgical specialty 4 or 5 23 (12.) 72 (10.4) 53 (19.3) ody mass index (BMI), kg m ⁻² Colorectal 110 02 (49.5) 72.0 (0.0) 134 (12.5) orthopactics 111 4 (10.0) - 457 (13.) - 156 (22.1) orthopactics 111 4 (10.0) - 457 (13.) 156 (22.1) - - urgical specialty Urper G1 837 (13.) - - - - Burns and plastics 460 (2.1) - - - - fleganery' None 657 (13.) 153 (17.3) 1023 (17.3) 1023 (17.3) 1023 (17.3) 1023 (17.3) <td>Patient characteristics</td> <td></td> <td></td> <td></td> <td></td>	Patient characteristics				
interim 12 326 (rs.5) 4067 (s6.3) 3499 (s1.2) SA physical status 1 2354 (10.6) 609 (12.7) 531 (9.3) SA physical status 1 13 428 (60.4) 4528 (62.5) 709 (29.9) ody mass index (BMI), kg m ⁻¹ 1 1002 (49.5) 720 (100.0) 1241 (23.5) urgical specialty Colorectal 110 002 (49.5) 7230 (100.0) 1241 (23.5) Hepatobiliary 2015 (9.1) - 1264 (27.1) Orthopaedics 1144 (5.0) - 283 (13.3) Upper G1 1815 (8.2) - - Upper G1 571 (33.0) - - Upper G1 571 (33.0) - - G7macology 297 (12.5) - - G7macology 294 (12.1) - - G7macology 297 (13.2) - - G7macology 297 (13.5) 123 (17.3) 1032 (13.7) G7macology 497 (13.2) - - G7macology 497 (12.2) 7			66 (56–73)	68 (60-75)	67 (58–73)
SA physical status 1 1 235 (10.5) 800 (11.2) 531 ($\hat{p}_{}$) 3 13 (428 (60.4) 4528 (c) 3420 (S) 1709 (S) 4 or 5 27.1 (24) 50.1 27.1 (24) 53 (25) 1709 (25) 4 or 5 27.1 (24) 50.1 27.1 (24) 50.1 27.4 (24) Urgical specialty Colorectal 110 (20) 72.1 (24) 50.1 27.4 (24) 110 (20) 72.1 (24) 50.1 27.4 (24) 110 (25) Hepatobiliary 2015 (9) - 12.9 (10) 12.64 (22) 110 (25) 72.0 (10) 12.64 (22) 111 (25) 72.0 (10) 72.8 (13) 112 (25) 72.0 (10) 72.8 (13) 114 (50) - 12.64 (22) 115 (25) - 12.64 (22) 116 (25) - 12.64 (22) 117 (32) - 12.64 (22) 118 (32) - 12.64 (22) 119 (25) - 12.64 (22) 110 (27) - 12.64 (27) - 12.64 (27) 110 (27) - 12.64 (27) - 12.74 (27) - 12.74 (27) 111 (27) - 12.74 (27) - 12.74 (27) - 12.74 (27) - 12.74 (27) - 12.74 (27) - 12.74 (27) - 12.74 (27] - 12.74 (27) - 12.74 (27] - 12.74 (27] - 12.74 (· · ·		
2 13 426 (i0.) 4326 (i0.) 4326 (i0.) 1326 (i0.) 1340 (i0.) 04 mass index (BMI), kg m ⁻¹ 4 or S 243 (1.) 72 (1.0) 53 (0.9) urgical specialty Colorectal 11002 (49.5) 7230 (100.0) 1341 (23.5) Hepatobiliary Colorectal 11002 (49.5) 7230 (100.0) 1341 (23.5) Hepatobiliary Colorectal 114 (5.0) - 427 (7.5) Thoracics 1141 (5.0) - 427 (7.5) - Upper GI 837 (3.8) - - - Burns and plastics 460 (2.1) - - - Vaacular 163 (0.7) - - - Head and neck 543 (2.4) - - - Vaacular 163 (0.7) - - - Vaacular 163 (0.7) - - - Vaacular 163 (0.7) 539 (7.3) 1402 (24.5) 1100 (12.8) Trate 60-90 beats min ⁻¹ 529 (1.1) 1102 (12.8) 11		1			
36190 (22.9)1200 (25.2)1006 (29.9)ody mass index (18M), kg m ⁻²)4 or 52/3 (1.2)72 (1.0430.8)2/3 (1.4)urgical specialtyColorectal11 002 (49.5)7230 (100.0)134 (1.5.5)Hepatobiliary2015 (9.1)-1264 (22.1)Orthopaedics1114 (5.0)-758 (13.3)Urbology2771 (12.3)1264 (22.1)Orthopaedics1114 (5.0)Urbology2771 (12.3)Burns and plastics460 (2.1)Abdominal - other788 (13.3)Burns and plastics460 (2.1)Adcular496 (2.2)Adcular6957 (13.1)1125 (17.3)1402 (24.5)Spinal496 (2.2)None6957 (13.1)113 (10.0)3281 (57.4)Adcular6957 (13.1)113 (10.0)3281 (57.4)Adcular12.32 (77.6)586 (77.3)4419 (77.3)Adr stat >00 beats12.32 (77.6)586 (77.3)4419 (77.3)ardiac signs*Nodal metastases3246 (14.6)859 (17.3)930 (14.7)Adr stat >00 beats1529 (77.0)5250 (72.6)4104 (73.6)ardiac signs*Nofalure1529 (77.0)5250 (72.6)4104 (73.6)Adr stat >00 beats1111327 (14.2)152 (12.2)141 (2.0)ardiac signs*None18 666 (24.1)613	ASA physical status		• . • .		
4 or S 24 (1, 1) 72 (1, 0) 53 (0, 9) orgin mass index (BML), kg m ⁻² Colorectal 11 002 (49.5) 7230 (100.0) 1341 (23.5) urgical specialty Colorectal 11 1002 (49.5) 7230 (100.0) 1341 (23.5) 1341 (23.5) Orthopaedics 1114 (5.0) - 427 (7.5) 1341 (23.5) 141 (23.5) Urolegy 2771 (12.5) - 1233 (3.7) 1923 (3.7) Urolegy 2971 (12.5) - - - Burns and plastics 460 (2.1) - - - Gynaecology 294 (1.3) - - - - Idaignancy" None 6957 (31.3) 1253 (17.3) 1402 (24.5) Primary only 12 015 (7.6) 589 (1.7) 1303 (18.0) 0.0 CG finding" Normal 17 327 (7.6) 589 (7.3) 1419 (7.3) Af rate 60-90 beats min ⁻³ 292 (3.7) 317 (4.4) 205 (3.6) ardiac signs" No faiture 16 202 (7.4) 182 (2.1) 1818 (2.1) 185					
ody mass index (BML) kg m ⁻² urgical specialty Colorectal 1007(945) 7230 (100.0) 1341 (23.5) Hepatobiliary 2015 (3.1) - 230 (100.0) 1341 (23.5) Urology 2711 (12.5) - 1		3	6190 (27.9)	1820 (25.2)	1709 (29.9)
ody mass index (BMI), kg m ⁻⁷ · 27, 124,0-30, 8 27, 124,1-30,2 27, 45 (24,33,1), urgical specialty Correctal 1002 (49,5) 7230 (100,0) 1341 (23.5) Hepatobiliary 2015 (3.1) - 230 (100,0) 1341 (23.5) Orthopaedics 1114 (s.0) - (24.7) 7,5 Thoracics 1815 (8.2) - (24.7) 7,5 Thoracics 1815 (8.2) - (24.7) 7,5 Thoracics 1815 (8.2) - (24.7) 7,5 Urplogy 2711 (12.5) - (24.7) 7,5 Urplogy 2711 (12.5) - (24.7) 7,5 Head and plastics 460 (2.1) - (24.7) 7,5 Head and neck 543 (2.4) - (24.7) 7,5 Head and neck 543 (2.4) - (24.7) 7,5 Vascular 163 (0.7) 17,2 Vascular 1,2 Vascular		4 or 5	243 (1.1)	72 (1.0)	53 (0.9)
urgical specialty i i i i i i i i i i i i i i i i i i i	Sody mass index (BMI) kg m ⁻²				• •
Heratobiliary2015 $(9,1)$ 1264 $(22,1)$ (22,1) (27,1) (25,1)Orthopaedics1114 $(5,0)$ -758 $(13,3)$ (25,2)Thoracics1815 $(8,2)$ -758 $(13,3)$ (25,2)Upology2771 $(12,5)$ Upology2771 $(12,5)$ Upology2771 $(12,5)$ Upology2771 $(12,5)$ Burna and plastics460 (2.1) Oracology294 (1.3) Cynacology294 (1.3) Vascular163 $(0,7)$ talignancy"None6957 $(31,3)$ 1253 $(17,3)$ 1402 $(24,5)$ None6957 $(31,3)$ 1253 $(17,3)$ 1402 $(24,5)$ Af rate 60-90 beats min ⁻¹ 293 $(11,7)$ 902 $(12,5)$ 731 $(12,8)$ ardiac signs"Norfal dure1559 $(7,0)$ 422 $(5,8)$ 4419 $(7,3)$ ardiac signs"No falure1552 $(7,0)$ 422 $(7,8)$ 419 $(7,3)$ ardiac signs"No falure1552 $(7,0)$ 424 $(2,3,6)$ 419 $(7,3)$ ardiac signs"No falure1552 $(7,0)$ 424 $(7,8)$ No falure1552 $(7,0)$ 420 $(7,8)$ 419 $(7,3)$ ardiac signs"No falure1552 $(7,0)$ 424 $(7,8)$ ardiac signs"No falure1652 $(7,4)$ 552 $(7,2)$ 424 $(7,8)$ ardiac signs"No falure1552 $(7,0)$ 410 $(7,3)$ ardiac signs"No falure1552 $(7,0)$ 424 $($		Colorectal	•		
Orthopaedics1114 (\$.0)-427 (7.5)Thoracics1115 (\$2.2)-758 (13.3)Urology2771 (12.5)-1923 (3.7)Upper G1837 (3.8)Burns and plastics460 (7.1)Burns and plastics460 (7.1)Head and neck543 (2.4)Spinal496 (2.2)Vascular163 (0.7)Taignancy*None5957 (31.3)1253 (17.3)1328 (57.4)Nodal metastases3246 (14.6)589 (7.7)3281 (57.4)Nodal metastases3246 (14.6)589 (7.7)419 (77.3)AF rate 50-beats min ⁻¹ 528 (1.7)902 (12.5)731 (12.8)min - ¹ /other abnormality578 (7.3)1422 (5.8)4119 (77.3)ardiac signs*No failure16 620 (74.8)5250 (72.6)4204 (73.6)min - ¹ /other abnormality118 (25.1)198 (25.1)199 (24.4)min - ¹ /other abnormality118 (25.1)128 (25.1)128 (25.1)yspnoea'II1337 (14.9)1158 (16.0)903 (15.8)IIII317 (14.9)1158 (16.0)903 (15.8)IIII135 (24.6)579 (12.2)4674 (81.8)yspnoea'III or IV644 (2.9)200 (2.8)136 (2.4)yspnoea'III or IV641 (2.9)200 (2.8)136 (2.4)yspnoea'III or IV641 (2.9)200 (2.8)136 (2.4)yspnoea' <td>Surgical specialty</td> <td></td> <td></td> <td>7250 (100.0)</td> <td></td>	Surgical specialty			7250 (100.0)	
Thoracics1815 (8.2)-758 (13.3)Upper GI837 (3.8)Abdominal - other708 (2.2)Gynaecology294 (1.3)Gynaecology294 (1.3)Gynaecology294 (1.3)Head and neck543 (2.4)Spiral466 (2.1)Spiral466 (2.2)Spiral466 (2.2)Spiral466 (2.3)1253 (17.3)1402 (24.5)Spiral466 (2.1)5118 (70.8)3281 (57.4)Spiral120 (54.1)5118 (70.8)3281 (57.4)Modal metastases3246 (14.6)859 (11.9)1030 (18.0)Af rate 60-90 beats min ⁻¹ 229 (12.7)317 (4.4)205 (5.6)Af rate so boeats258 (17.7)317 (4.4)205 (5.6)204 (7.5)ardiac signs'Nof allure15 59 (7.0)422 (5.8)4419 (77.3)Mot documented1559 (7.0)422 (5.8)4419 (7.3)ardiac signs'No failure16 620 (74.8)5250 (72.6)4204 (7.6)Mot documented1559 (7.0)422 (5.8)114 (2.0)eart failure (NYHA) classI11337 (14.9)1158 (16.0)903 (15.8)II or IV646 (2.1)162 (2.2)114 (2.0)633 (3.8)sepiratory infection in precedingNon-insulin dependent2789 (12.6)879 (12.6)881 (13.7)iabets mellitusNon-insulin dependent219 (5				—	
		Orthopaedics	1114 (5.0)	—	427 (7.5)
Urology2771 (12.5)-1923 (33.7)Uroper G1837 (3.8)Abdominal - other708 (3.2)Burns and plastics460 (2.1)Gynaecology294 (1.3)Head and neck543 (2.4)Spinal496 (2.2)Vascular153 (0.7)Falignancy"Noda Imetastases326 (1.4)559 (1.9)1030 (18.0)CG findings"Normal17 232 (77.6)5589 (7.3)4419 (77.3)AF rate 60-90 beats27.30377 (4.4)205 (3.6)AF rate 50 beats258 (1.7)902 (12.5)7.31 (12.8)min "-toher abnormalityardiac signs"Not documented1559 (7.0)422 (5.8)4419 (77.3)ardiac signs"No falure166 (24.1)132 (25.1)138 (24.1)ardiac signs"No falure165 (21.1)1318 (25.1)135 (24.4)illure (NYHA) classI18 276 (22.572 (81.2)4674 (81.8)II110 rV644 (2.9)200 (2.8)136 (2.4)yaponea"None128 66 (84.1)6133 (84.8)4750 (83.1)yaponea"None18 66 (84.1)6133 (84.8)4750 (83.1)yaponea"None18 666 (84.1)6133 (84.8)4750 (83.1)yaponea"None18 66 (84.1)613 (84.8)4750 (83.1)yaponea"None18 66 (84.1)613 (80.3)616 (1.6)yaponea		Thoracics	1815 (8.2)	_	758 (13.3)
		Urology		_	
		6,5			
Burns and plastics460 (2.1) (7.10)Gynaecology294 (1.3)Head and neck543 (2.4)Spinal496 (2.2)Vascular163 (0.7)talignancy"None6957 (31.3)1253 (17.3)1202 (24.5)Normal17 252 (7.6)5589 (77.3)1241 (7.3)2050 (18.0)CG findings"Normal17 22 (7.6)5589 (77.3)4419 (77.3)AF rate 60-90 beats min ⁻¹ 2529 (3.7)317 (4.4)205 (3.6)AF rate 60-90 beats min ⁻¹ 559 (7.0)922 (12.5)4419 (77.3)ardiac signs"No failure1559 (7.0)922 (12.5)4419 (77.3)ardiac signs"No failure1559 (7.0)822 (5.2)474 (4.6)ardiac signs"No failure1559 (7.0)822 (5.2)114 (2.0)ardiac signs"No failure1559 (7.0)158 (2.2)114 (2.0)ardiac signs"No failure16 (2.0)1138 (2.5)135 (2.4)ardiac signs"No failure16 27 (82.2)144 (2.0)200 (2.8)135 (2.4)ardiare figure10 r IV644 (2.9)200 (2.8)135 (2.4)137 (1.4)yspnoea"III or IV644 (2.9)200 (2.8)135 (2.4)arebrovacular disease-18 696 (8.1)613 (8.8)757 (8.3.1)rebrovacular disease-238 (1.3)216 (3.0)128 (3.2)rebrovacular disease-238 (1.4)230 (3.2)211 (4.0)					
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$				_	_
Head and meck543 (2.4) $ -$ Spinal496 (2.2) $ -$ falignancy"163 (0.7) $ -$ None6957 (31.3)1253 (17.3)1402 (24.5)Primary only12 015 (54.1)5118 (70.8)3281 (57.4)CG findings"Normal12 015 (54.1)5189 (77.3)4419 (77.3)AF rate 60-90 beats min ⁻¹ 2529 (3.7)317 (4.4)205 (3.6)AF rate 60-90 beats min ⁻¹ 2529 (1.7.3)902 (12.5)731 (12.8)min ⁻¹ /other abnormalitymin ⁻¹ /other abnormality1559 (7.0)422 (5.8)4419 (77.3)ardiac signs"No failure1559 (7.0)5250 (72.6)4204 (75.6)Ath trate >00 beats1559 (7.0)1818 (25.1)1395 (24.4)diuretic, digoxin110 r1V644 (2.9)200 (2.8)136 (2.4)etart failure (NYHA) classI18 257 (82.2)5872 (81.2)4674 (81.8)III or IV644 (2.9)200 (2.8)136 (2.4)yspnoea"None18 696 (84.1)613 (84.8)4750 (83.1)On exertion18 597 (80.1)663 (0.6)183 (3.0)182 (3.2)erebrovacular disease877 (4.0)333 (1.3)218 (3.0)182 (3.2)erementa199 (1.2)368 (51.0)211 (44.0)ibabetes mellitusNon-insulin dependent239 (2.9)2387 (3.0)213 (3.5)iver disease233 (1.0)52 (0.7)67 (1.5)moch239 (2.6)668 (51.0)251 (44.0)iver disease <td></td> <td>Burns and plastics</td> <td>460 (2.1)</td> <td>-</td> <td>—</td>		Burns and plastics	460 (2.1)	-	—
Head and meck543 (2.4) $ -$ Spinal496 (2.2) $ -$ falignancy"163 (0.7) $ -$ None6957 (31.3)1253 (17.3)1402 (24.5)Primary only12 015 (54.1)5118 (70.8)3281 (57.4)CG findings"Normal12 015 (54.1)5189 (77.3)4419 (77.3)AF rate 60-90 beats min ⁻¹ 2529 (3.7)317 (4.4)205 (3.6)AF rate 60-90 beats min ⁻¹ 2529 (1.7.3)902 (12.5)731 (12.8)min ⁻¹ /other abnormalitymin ⁻¹ /other abnormality1559 (7.0)422 (5.8)4419 (77.3)ardiac signs"No failure1559 (7.0)5250 (72.6)4204 (75.6)Ath trate >00 beats1559 (7.0)1818 (25.1)1395 (24.4)diuretic, digoxin110 r1V644 (2.9)200 (2.8)136 (2.4)etart failure (NYHA) classI18 257 (82.2)5872 (81.2)4674 (81.8)III or IV644 (2.9)200 (2.8)136 (2.4)yspnoea"None18 696 (84.1)613 (84.8)4750 (83.1)On exertion18 597 (80.1)663 (0.6)183 (3.0)182 (3.2)erebrovacular disease877 (4.0)333 (1.3)218 (3.0)182 (3.2)erementa199 (1.2)368 (51.0)211 (44.0)ibabetes mellitusNon-insulin dependent239 (2.9)2387 (3.0)213 (3.5)iver disease233 (1.0)52 (0.7)67 (1.5)moch239 (2.6)668 (51.0)251 (44.0)iver disease <td></td> <td>Gynaecology</td> <td>294 (1.3)</td> <td>_</td> <td>_</td>		Gynaecology	294 (1.3)	_	_
SpinalApsoclarApsoclar-falignancy'None6957 (31.3)1253 (17.3)1402 (24.5)Primary only12 015 (54.1)5118 (70.8)3281 (57.4)Oc findings'Normal17 232 (77.6)5589 (73.3)4419 (77.3)AF rate 50-90 beats min ⁻¹ 259 (3.7)317 (4.4)205 (3.6)AF rate 50-90 beats min ⁻¹ 259 (1.7)920 (1.5)731 (12.8)ardiac signs'Nord ocumented1559 (7.0)422 (5.8)4419 (77.3)ardiac signs'No failure1559 (7.0)422 (5.8)4419 (77.3)ardiac signs'No failure165 (20 (7.8)5250 (72.6)4204 (73.6)ardiac signs'No failure1559 (7.0)422 (5.8)4419 (77.3)ardiac signs'No failure1559 (7.0)422 (5.8)4419 (77.3)ardiac signs'No failure158 (7.0)423 (2.8)457 (8.1)ardiac signs'No failure158 (7.0)422 (5.8)414 (7.0)ardiac signs'II18 257 (82.2)525 (72.6)4204 (73.6)ardiac signs'No ne462 (2.1)152 (2.2)114 (2.0)ardiac signs'II18 257 (82.2)525 (72.6)4204 (73.6)ardiac signs'None462 (2.1)152 (8.2)526 (72.6)4204 (73.6)ardiac signs'II10 or IV464 (2.9)200 (2.8)136 (2.4)yspance'None168 267 (82.2)526 (72.6)4204 (82.3)ardiac signs'None278 (12.6)873 (13.0) <td< td=""><td></td><td></td><td></td><td>_</td><td>_</td></td<>				_	_
vacular 163 (0.7) - - falignancy" None 657 (31.3) 1253 (17.3) 1402 (24.5) Primary only 12 015 (54.1) 5118 (70.8) 3281 (57.4) Nodal metastases 3246 (14.6) 859 (17.3) 1419 (77.3) AF rate 50-90 beats min ⁻¹ 829 (3.7) 317 (4.4) 205 (3.6) AF rate 50-90 beats min ⁻¹ 829 (3.7) 902 (12.5) 419 (77.3) ardiac signs" No failure 16 620 (74.8) 5250 (72.6) 4204 (73.6) ardiac signs" No failure (16 goxin 118 (27.1) 118 (27.1) 1395 (24.4) ardiac signs" II or IV 827 (82.2) 587 (81.3) 1395 (24.6) min"-iventine exertion 3137 (14.9) 1158 (2.2) 114 (2.0) teart failure (NYHA) class II or IV 829 (82.0) 5136 (23.1) 158 (26.4) tyspnoea" None 18 696 (84.1) 6133 (34.8) 4750 (83.1) teart failure (NYHA) class II or V 789 (12.6) 79 (12.2) 781 (13.7) teart failure (NYHA) class <td< td=""><td></td><td></td><td></td><td></td><td></td></td<>					
falignancy"None6957 (31 x)1203 (7.3)1402 (24 5)Primary only12 015 (54.1)5118 (70.8)3281 (57.4)Nodal metastases3246 (14.6)859 (17.3)3281 (57.4)AF rate 500 beats min ⁻¹ 17 232 (77.6)5580 (77.3)4419 (77.3)AF rate 500 beats min ⁻¹ 259 (1.7)920 (12.5)731 (12.8)ardiac signs"Not documented1559 (7.0)422 (5.8)4119 (77.3)ardiac signs di l'intypertensive,1559 (7.0)422 (5.8)4129 (7.3)ardiac signs di l'intypertensive,1559 (7.0)452 (5.1)423 (5.2)ardiac signs di l'intypertensive,159 (7.4)1559 (7.6)451 (7.1)ardiac signs di l'intypertensive, <td></td> <td>-</td> <td></td> <td>—</td> <td>-</td>		-		—	-
Primary only Nodal metastases 12 015 (5.4 1) 5118 (70.8) 3281 (57.4) CG findings* Normal 17 232 (77.6) 5589 (77.3) 4419 (77.3) AF rate 60–90 beats min ⁻¹ AF rate 50 beats 2598 (11.7) 902 (12.5) 731 (12.8) ardiac signs* AF rate 50 beats 2598 (17.7) 912 (12.5) 4419 (77.3) ardiac signs* No failure 16 520 (74.8) 5250 (72.6) 4204 (73.6) ardiac signs* No failure 16 520 (74.8) 5250 (72.6) 4204 (73.6) ardiac signs* I 18 257 (82.2) 5872 (81.2) 4674 (81.8) iurretic, digoxin Peripheral oedema 462 (2.1) 162 (2.2) 114 (2.0) teart failure (NYHA) class II 3127 (14.9) 1158 (15.0) 933 (15.8) III or IV 644 (2.5) 200 (2.8) 879 (12.2) 781 (13.7) spinatory infection in preceding None 18 696 (84.1) 6133 (84.8) 4750 (83.1) or exertion 2789 (12.6) 879 (12.2) 781 (13.7) 128 (13.7) timiting exertion/ar trast <			• • • •	-	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Malignancy*	None	6957 (31.3)	1253 (17.3)	1402 (24.5)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		Primary only	12 015 (54.1)	5118 (70.8)	3281 (57.4)
GG findings* Normal 17 232 (77, 6) S58 (77, 3) 4419 (77, 3) AF rate 5-90 beats 293 (3.7) S17 (4.4) 205 (3.6) AF rate >90 beats 2298 (1.7) 902 (12.5) 731 (12.8) ardiac signs* Not documented 1559 (7.0) 422 (5.8) 4419 (77.3) ardiac signs* No failure 16 520 (74.8) 5250 (72.6) 4204 (73.6) Antihypertensive, 5136 (23.1) 1818 (25.1) 1395 (24.4) diuretic, digoxin 16 22 (2.1) 162 (2.2) 114 (2.0) eart failure (NYHA) class I 18 257 (82.2) 587 (12.2) 781 (13.8) II None 18 266 (84.1) 613 (84.8) 4750 (83.1) yspnoea* None 18 696 (84.1) 613 (84.8) 4750 (83.1) reterion 2789 (12.6) 879 (12.2) 781 (13.7) sepiratory infection in preceding 733 (3.3) 218 (3.0) 182 (3.2) month 781 (3.5) 247 (3.4) 218 (3.8) indetesse 161 (0.7) 48 (0.7) 41 (0.7) isbets mellitus Non-insulin dependent 758 (3.4)		5 5			
AF rate $0-90$ beats min ⁻¹ AF rate >90 beats min ⁻¹ /other abnormality 317 (4.4) 205 (3.6) 2598 (11.7) 902 (12.5) 731 (12.8) 731 (12.8)ardiac signs"Not documented divertic, digoxin 1559 (7.0) 422 (5.8) 4419 (77.3) 1529 (72.6)ardiac signs"Not failure divertic, digoxin 16 (20 (78.8) 5250 (72.6) 4204 (73.6) 1205 (24.4) divertic, digoxinardiac signs"Not failure divertic, digoxin 16 (20 (78.8) 5250 (72.6) 4204 (73.6)teart failure (NYHA) classI 18 (3257 (82.2) 5872 (81.2) 4674 (81.8) 1158 (16.0) 903 (15.8)user failure (NYHA) classIIII 3137 (14.9) 1158 (16.0) 903 (15.8)user failure (NYHA) classIIII 3137 (14.9) 1158 (16.0) 903 (15.8)user failure (NYHA) classIIII 113317 (14.9) 1158 (16.0) 903 (15.8)user failure (NYHA) classIIII 113317 (14.9) 1158 (16.0) 903 (15.8)user failure (NYHA) classIIII 113317 (14.9) 1158 (16.0) 200 (2.8) 136 (2.4)user failure (NYHA) classIIII 113317 (14.9) 1158 (16.0) 2131 (14.0)user failure (NYHA) classIIII 113317 (14.9) 116 (2.0) 110.7)user failure (NYHA) classNon-insulin dependent 2789 (12.6) 879 (12.2) 781 (13.9) 2218 (3	CC findings*		· · ·		
AF rate >90 beats 2596 (11.7) 902 (12.5) 731 (12.8) ardiac signs" Not documented 1559 (7.0) 422 (5.8) 4419 (77.3) ardiac signs" No failure 16 620 (74.8) 5250 (72.6) 4204 (73.6) antihypertensive, 5136 (23.1) 1818 (25.1) 1395 (24.4) diuretic, digoxin Pripheral oedema 462 (2.1) 162 (2.2) 114 (2.0) ieart failure (NYHA) class I 18 257 (82.2) 5872 (81.2) 4674 (81.8) II or IV 644 (2.9) 200 (2.8) 136 (2.4) 133 (2.4) yspnoea" None 18 696 (84.1) 6133 (84.8) 4750 (83.1) or exertion 2789 (12.6) 879 (12.2) 781 (13.7) sepiratory infection in preceding 731 (3.5) 247 (3.4) 218 (3.8) month 738 (3.4) 230 (3.2) 219 (3.8) erebrovascular disease Non-insulin dependent 718 (3.7) 247 (3.4) 218 (3.8) iver disease Ver smoked 10 509 (47.3) 3688 (51.0) 2511 (44.0) iver dise	CG IIIuiiigs				
ardiac signs" Not documented 1559 (7.0) 422 (5.8) 4419 (77.3) Not documented 1559 (7.0) 422 (5.8) 4420 (73.6) Antihypertensive, 5136 (23.1) 1818 (25.1) 1395 (24.4) diuretic, digoxin Peripheral ocdema 462 (2.1) 162 (2.2) 114 (2.0) 1818 (25.1) 1395 (24.4) diuretic, digoxin Peripheral ocdema 462 (2.1) 162 (2.2) 114 (2.0) 181 (2.2) 4674 (81.8) I I 1 13317 (14.9) 1158 (16.0) 903 (15.8) III or IV 644 (2.9) 200 (2.8) 136 (2.4) None 18 696 (84.1) 6133 (84.8) 4750 (83.1) On exertion 2789 (12.6) 879 (12.2) 781 (13.7) Limiting exertion/at rest 733 (3.3) 218 (3.0) 182 (3.2) espiratory infection in preceding month rerebrovascular disease 874 (0.0) 300 (4.1) 240 (4.2) insulin-dependent 2194 (9.9) 766 (10.6) 608 (10.6) insulin-dependent 233 (1.0) 52 (0.7) 87 (1.5) moking History Never smoked 10 509 (47.3) 3688 (51.0) 2511 (44.0) X.A operative severity Complex/major 1124 (5.1) 272 (3.8) 286 (5.0) Current smoker 2367 (10.7) 624 (8.6) 641 (11.2) including index procedure 12 including index procedure 12 2 or more 893 (4.0) 259 (26.3) 403 (55.7) 401 (7.0) perations in preceding month, 1 21 322 (96.0) 718 (97.1) 5441 (95.2) including index procedure 12 2 or more 893 (4.0) 211 (2.9) 272 (4.8) lanned postoperative level of care 12 Vard 10					
			2598 (11.7)	902 (12.5)	731 (12.8)
ardiac signs" No failure 16 620 (74.8) 5250 (72.6) 4204 (73.6) Antihypertensive, 5136 (23.1) 1818 (25.1) 1395 (24.4) iduretic, digoxin Peripheral oedema 462 (2.1) 162 (2.2) 114 (2.0) eart failure (NYHA) class I 1 3317 (14.9) 1158 (16.0) 903 (15.8) II 3317 (14.9) 1158 (16.0) 903 (15.8) II 0 TV 644 (2.9) 200 (2.8) 136 (2.4) Ysppnoea" None 18 696 (84.1) 6133 (84.8) 4750 (83.1) On exertion 2789 (12.6) 879 (12.2) 781 (13.7) Limiting exertion/at rest 733 (3.3) 218 (3.0) 182 (3.2) eepiratory infection in preceding month erebrovascular disease 71 (13.5) 247 (3.4) 218 (3.8) month erebrovascular disease 71 (13.5) 247 (3.4) 218 (3.8) month erebrovascular disease 73 (3.6) 219 (3.8) 240 (4.2) insulin-dependent 758 (3.4) 230 (3.2) 219 (3.8) insulin-dependent 758 (3.4) 230 (3.2) 219 (3.8) insulin-dependent 758 (3.4) 230 (3.2) 219 (3.8) isex smoker >6 months 7299 (23.9) 2387 (33.0) 2013 (35.2) Ex-smoker >6 months 7299 (23.9) 2387 (33.0) 2013 (35.2) Ex-smoker <6 months 729 (23.9) 2387 (33.0) 2013 (35.2) isex smoker <6 months 729 (23.9) 2387 (33.0) 2013 (35.2) isex smoker <6 months 729 (23.9) 2387 (33.0) 2013 (35.2) isex smoker <6 months 719 (23.9) 2387 (33.0) 2013 (35.2) isex smoker <6 months 719 (24.9) 624 (8.6) 641 (11.2) Not known 919 (4.1) 259 (3.6) 262 (4.6) irgency of surgery Elective 20 077 (90.4) 6432 (89.0) 5180 (90.7) incturent smoker 267 (10.7) 624 (8.6) 641 (11.2) Not known 919 (4.1) 259 (3.6) 262 (4.6) irgency of surgery Elective 20 077 (90.4) 6432 (89.0) 5130 (90.7) inctuding index procedure including i			1	400 (5.0)	4440 (77.0)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$				· · /	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	ardiac signs*		16 620 (74.8)		4204 (73.6)
Peripheral oedema452 (2.1)152 (2.2)114 (2.0)leart failure (NYHA) class118 257 (82.2)5872 (81.2)4674 (81.8)IIII3317 (14.9)1158 (16.0)903 (15.8)yspnoea*None186 96 (84.1)6133 (84.8)4750 (83.1)on exertion2789 (12.6)879 (12.2)781 (13.7)umiting exertion/at rest733 (3.3)218 (3.0)182 (3.2)espiratory infection in precedingresertion/at rest781 (3.5)247 (3.4)208 (3.8)monthreterbrovascular disease887 (4.0)300 (4.1)240 (4.2)iabetes mellitusNon-insulin dependent2194 (9.9)766 (10.6)608 (10.6)iabetes mellitusNon-insulin dependent2194 (9.9)766 (10.6)608 (10.6)iabetes mellitusNon-insulin dependent2194 (9.9)220 (7)87 (1.5)moking HistoryNever smoked10 509 (47.3)3688 (51.0)2511 (44.0)Ex-smoker >6 months729 (32.9)2387 (33.0)2013 (55.2)Ex-smoker 2367 (10.7)624 (8.6)641 (11.2)rgency of surgeryElective2077 (90.4)6432 (89.0)5180 (90.7)KA operative severityComplex/major14 156 (63.7)3200 (44.3)5312 (93.0)XA operative severityComplex/major14 156 (63.7)3000 (44.3)5312 (93.0)Mot horw191 (4.1)219 (2.6)798 (11.0)533 (9.3)XA operative severityComplex/major14 156 (63.7)3000 (44.3) <td></td> <td></td> <td>5136 (23.1)</td> <td>1818 (25.1)</td> <td>1395 (24.4)</td>			5136 (23.1)	1818 (25.1)	1395 (24.4)
ieart failure (NYHA) class I 18 257 (82.2) 587 (81.2) 4674 (81.8) III III or IV 644 (2.9) 200 (2.8) 136 (2.4) hyspnoea* None 18 696 (84.1) 6133 (84.8) 4750 (83.1) on exertion 2789 (12.6) 879 (12.2) 781 (13.7) espiratory infection in preceding 781 (3.5) 247 (3.4) 218 (3.8) month - 781 (3.5) 247 (3.4) 218 (3.8) retebrovascular disease 887 (4.0) 300 (4.1) 240 (4.2) iabetes mellitus Non-insulin dependent 2194 (9.9) 766 (10.6) 608 (10.6) iver disease Insulin-dependent 259 (32.9) 238 (13.0) 211 (3.8) iver disease Never smoked 10 509 (47.3) 3688 (51.0) 251 (44.0) Ex-smoker >6 months 1124 (5.1) 272 (3.8) 286 (5.0) Irgency of surgery Elective 200 77 (90.4) 6432 (89.0) 5180 (90.7) irgency of surgery Elective 200 77 (90.4) 6432 (89.0) 5180 (90.7)			462 (2.1)	162 (2.2)	114 (2.0)
II3317 (14.9)1158 (16.0)903 (15.8)hyspnoea"III or IV644 (2.9)200 (2.8)136 (2.4)None18 696 (84.1)6133 (84.8)4750 (83.1)On exertion2789 (12.6)879 (12.2)781 (13.7)Limiting exertion/at rest733 (3.3)218 (3.0)182 (3.2)espiratory infection in preceding781 (3.5)247 (3.4)218 (3.8)month	Jeart failure (NYHA) class				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$					
$\begin{array}{cccccccccccccccccccccccccccccccccccc$. ,	• •
)yspnoea*	None	18 696 (84.1)	6133 (84.8)	4750 (83.1)
espiratory infection in preceding month 781 (3.5) 247 (3.4) 218 (3.8) month repervovascular disease 887 (4.0) 300 (4.1) 240 (4.2) ememtia 161 (0.7) 48 (0.7) 41 (0.7) biabetes mellitus Non-insulin dependent 2194 (9.9) 766 (10.6) 608 (10.6) iver disease 233 (1.0) 52 (0.7) 87 (1.5) moking History Never smoked 10 509 (47.3) 3688 (51.0) 2511 (44.0) Ex-smoker >6 months 7299 (32.9) 2387 (33.0) 2013 (35.2) Ex-smoker <6 months		On exertion	2789 (12.6)	879 (12.2)	781 (13.7)
espiratory infection in preceding month 781 (3.5) 247 (3.4) 218 (3.8) month repervovascular disease 887 (4.0) 300 (4.1) 240 (4.2) ememtia 161 (0.7) 48 (0.7) 41 (0.7) biabetes mellitus Non-insulin dependent 2194 (9.9) 766 (10.6) 608 (10.6) iver disease 233 (1.0) 52 (0.7) 87 (1.5) moking History Never smoked 10 509 (47.3) 3688 (51.0) 2511 (44.0) Ex-smoker >6 months 7299 (32.9) 2387 (33.0) 2013 (35.2) Ex-smoker <6 months		Limiting exertion/at rest			
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Respiratory infection in preceding				
erebrovascular disease 887 (4.0) 300 (4.1) 240 (4.2) erementia 161 (0.7) 48 (0.7) 41 (0.7) riabetes mellitus Non-insulin dependent 2194 (9.9) 766 (10.6) 608 (10.6) insulin-dependent 758 (3.4) 230 (3.2) 219 (3.8) iver disease 233 (1.0) 52 (0.7) 87 (1.5) moking History Never smoked 10 509 (47.3) 3688 (51.0) 2511 (44.0) Ex-smoker >6 months 7299 (32.9) 2387 (33.0) 2013 (35.2) Ex-smoker <6 months	. ,		x <i>i</i>		()
mementia 161 (0.7) 48 (0.7) 41 (0.7) piabetes mellitus Non-insulin dependent 2194 (9.9) 766 (10.6) 608 (10.6) iver disease 233 (1.0) 52 (0.7) 87 (1.5) moking History Never smoked 10 509 (47.3) 3688 (51.0) 2511 (44.0) Ex-smoker >6 months 7299 (32.9) 2387 (33.0) 2013 (35.2) Ex-smoker <6 months			887 (4 0)	300 (4 1)	240 (4.2)
biabetes mellitusNon-insulin dependent 2194 (9.9) 766 (10.6) 608 (10.6)iver disease 233 (1.0) 52 (0.7) 87 (1.5)moking HistoryNever smoked 10509 (47.3) 3688 (51.0) 2511 (44.0)Ex-smoker >6 months 7299 (32.9) 2387 (33.0) 2013 (35.2)Ex-smoker <6 months					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			• • • •		
iver disease 233 (1.0) 52 (0.7) 87 (1.5) moking History Never smoked 10 509 (47.3) 3688 (51.0) 2511 (44.0) Ex-smoker >6 months 7299 (32.9) 2387 (33.0) 2013 (35.2) Ex-smoker <6 months 1124 (5.1) 272 (3.8) 286 (5.0) Current smoker 2367 (10.7) 624 (8.6) 641 (11.2) Not known 919 (4.1) 259 (3.6) 262 (4.6) frgency of surgery Elective 20 077 (90.4) 6432 (89.0) 5180 (90.7) Expedited 2141 (9.6) 798 (11.0) 533 (9.3) XA operative severity Complex/major 14 156 (63.7) 3200 (44.3) 5312 (93.0) X-major 8062 (36.3) 4030 (55.7) 401 (7.0) perations in preceding month, 1 21 322 (96.0) 7018 (97.1) 5441 (95.2) including index procedure 2 lanned postoperative level of care 20 r or nore 893 (4.0) 211 (2.9) 272 (4.8) Level 1 2749 (12.4) 1056 (14.6) 622 (10.9) Level 2 or enhanced care 7913 (35.6) 2060 (28.5) 2354 (41.2) Level 3 915 (4.1) 107 (1.5) 235 (4.1) reoperative physiological and biochemical variables erum sodium (mmol L ⁻¹) $I40 (138-141)$ 140 (138-142) 140 (138-141)	nabetes mellitus				
iver disease 233 (1.0) 52 (0.7) 87 (1.5) moking History Never smoked 10 509 (47.3) 3688 (51.0) 2511 (44.0) Ex-smoker >6 months 7299 (32.9) 2387 (33.0) 2013 (35.2) Ex-smoker <6 months 1124 (5.1) 272 (3.8) 286 (5.0) Current smoker 2367 (10.7) 624 (8.6) 641 (11.2) Not known 919 (4.1) 259 (3.6) 262 (4.6) frgency of surgery Elective 20 077 (90.4) 6432 (89.0) 5180 (90.7) Expedited 2141 (9.6) 798 (11.0) 533 (9.3) XA operative severity Complex/major 14 156 (63.7) 3200 (44.3) 5312 (93.0) X-major 8062 (36.3) 4030 (55.7) 401 (7.0) perations in preceding month, 1 21 322 (96.0) 7018 (97.1) 5441 (95.2) Including index procedure 2 lanned postoperative level of care 20 r or more 893 (4.0) 211 (2.9) 272 (4.8) Level 1 2749 (12.4) 1056 (14.6) 622 (10.9) Level 2 or enhanced care 7913 (35.6) 2060 (28.5) 2354 (41.2) Level 3 915 (4.1) 107 (1.5) 235 (4.1) reoperative physiological and biochemical variables erum sodium (mmol L ⁻¹) $I40 (138-142)$ 140 (138-141)		Insulin-dependent	758 (3.4)	230 (3.2)	219 (3.8)
moking HistoryNever smoked10 509 (47.3)3688 (51.0)2511 (44.0)Ex-smoker >6 months7299 (32.9)2387 (33.0)2013 (35.2)Ex-smoker <6 months	iver disease		233 (1.0)		
$ \begin{array}{llllllllllllllllllllllllllllllllllll$		Never smoked	10 509 (47 3)		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$					
$ \begin{array}{cccc} \mbox{Current smoker} & 2367 (10.7) & 624 (8.6) & 641 (11.2) \\ \mbox{Not known} & 919 (4.1) & 259 (3.6) & 262 (4.6) \\ \mbox{Strongency} & Elective & 20 077 (90.4) & 6432 (89.0) & 5180 (90.7) \\ \mbox{Expedited} & 2141 (9.6) & 798 (11.0) & 533 (9.3) \\ \mbox{XA operative severity} & Complex/major & 14 156 (63.7) & 3200 (44.3) & 5312 (93.0) \\ \mbox{X-major} & 8062 (36.3) & 4030 (55.7) & 401 (7.0) \\ \mbox{perations in preceding month,} & 1 & 21 322 (96.0) & 7018 (97.1) & 5441 (95.2) \\ \mbox{including index procedure} & & & & & & & & \\ \mbox{lanned postoperative level of care} & 2 or more & 893 (4.0) & 211 (2.9) & 272 (4.8) \\ \mbox{Level 1} & 2749 (12.4) & 1056 (14.6) & 622 (10.9) \\ \mbox{Level 2 or enhanced care} & 7913 (35.6) & 2060 (28.5) & 2354 (41.2) \\ \mbox{Level 3} & 915 (4.1) & 107 (1.5) & 235 (4.1) \\ \mbox{reoperative physiological and biochemical variables} & & & & & & & & \\ \mbox{erum sodium (mmol L}^{-1}) & & & & 140 (138-141) & 140 (138-142) & 140 (138-141) \\ \end{array}$					· · ·
Not known919 (4.1)259 (3.6)262 (4.6)Irgency of surgeryElective20 077 (90.4)6432 (89.0)5180 (90.7)Expedited2141 (9.6)798 (11.0)533 (9.3)XA operative severityComplex/major14 156 (63.7)3200 (44.3)5312 (93.0)X-major8062 (36.3)4030 (55.7)401 (7.0)perations in preceding month,121 322 (96.0)7018 (97.1)5441 (95.2)including index procedure2 or more893 (4.0)211 (2.9)272 (4.8)lanned postoperative level of care2 or more893 (4.0)211 (2.9)272 (4.8)Level 12749 (12.4)1056 (14.6)622 (10.9)Level 2 or enhanced care7913 (35.6)2060 (28.5)2354 (41.2)Level 3915 (4.1)107 (1.5)235 (4.1)reoperative physiological and biochemical variables140 (138–141)140 (138–142)140 (138–141)					. ,
Not known919 (4.1)259 (3.6)262 (4.6)Irgency of surgeryElective20 077 (90.4)6432 (89.0)5180 (90.7)Expedited2141 (9.6)798 (11.0)533 (9.3)XA operative severityComplex/major14 156 (63.7)3200 (44.3)5312 (93.0)X-major8062 (36.3)4030 (55.7)401 (7.0)pperations in preceding month,121 322 (96.0)7018 (97.1)5441 (95.2)including index procedure2 or more893 (4.0)211 (2.9)272 (4.8)lanned postoperative level of care2 or more893 (4.0)211 (2.9)272 (4.8)Level 12749 (12.4)1056 (14.6)622 (10.9)Level 2 or enhanced care7913 (35.6)2060 (28.5)2354 (41.2)Level 3915 (4.1)107 (1.5)235 (4.1)reoperative physiological and biochemical variables140 (138–141)140 (138–142)140 (138–141)		Current smoker	2367 (10.7)	624 (8.6)	641 (11.2)
IntegrationElective $20 \text{ 077} (90.4)$ $6432 (89.0)$ $5180 (90.7)$ Expedited $2141 (9.6)$ $798 (11.0)$ $533 (9.3)$ XA operative severityComplex/major $14 156 (63.7)$ $3200 (44.3)$ $5312 (93.0)$ X-major $8062 (36.3)$ $4030 (55.7)$ $401 (7.0)$ perations in preceding month,1 $21 322 (96.0)$ $7018 (97.1)$ $5441 (95.2)$ including index procedure2 or more $893 (4.0)$ $211 (2.9)$ $272 (4.8)$ lanned postoperative level of care $2 0 \text{ more}$ $893 (4.0)$ $211 (2.9)$ $272 (4.8)$ Level 1 $2749 (12.4)$ $1056 (14.6)$ $622 (10.9)$ Level 2 or enhanced care $7913 (35.6)$ $2060 (28.5)$ $2354 (41.2)$ Level 3 $915 (4.1)$ $107 (1.5)$ $235 (4.1)$ reoperative physiological and biochemical variables $140 (138-141)$ $140 (138-142)$ $140 (138-141)$		Not known			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Irgency of surgery				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	- Serrey of Burgery				
X-major $8062 (36.3)$ $4030 (55.7)$ $401 (7.0)$ perations in preceding month, including index procedure1 $21 322 (96.0)$ $7018 (97.1)$ $5441 (95.2)$ lanned postoperative level of care2 or more $893 (4.0)$ $211 (2.9)$ $272 (4.8)$ lanned postoperative level of care2 or more $893 (4.0)$ $211 (2.9)$ $272 (4.8)$ lanned postoperative level of care2 or enhanced care $7913 (35.6)$ $2060 (28.5)$ $2354 (41.2)$ Level 12749 (12.4)1056 (14.6) $622 (10.9)$ Level 2 or enhanced care $7913 (35.6)$ $2060 (28.5)$ $2354 (41.2)$ Level 3915 (4.1)107 (1.5) $235 (4.1)$ reoperative physiological and biochemical variables140 (138–141)140 (138–142)140 (138–141)					. ,
$ \begin{array}{c} 1 & 21 322 (96.0) & 7018 (97.1) & 5441 (95.2) \\ \hline \\ 1 & 20 \ more & 893 (4.0) & 211 (2.9) & 272 (4.8) \\ 2 \ or \ more & 893 (4.0) & 211 (2.9) & 272 (4.8) \\ Ward & 10 \ 641 (47.9) & 4007 (55.4) & 2502 (43.8) \\ Level 1 & 2749 (12.4) & 1056 (14.6) & 622 (10.9) \\ Level 2 \ or \ enhanced \ care & 7913 (35.6) & 2060 (28.5) & 2354 (41.2) \\ Level 3 & 915 (4.1) & 107 (1.5) & 235 (4.1) \\ \end{array} $	XA operative severity	1 /			5312 (93.0)
$ \begin{array}{c} 1 & 21 322 (96.0) & 7018 (97.1) & 5441 (95.2) \\ \hline \\ 1 & 20 \ more & 893 (4.0) & 211 (2.9) & 272 (4.8) \\ 2 \ or \ more & 893 (4.0) & 211 (2.9) & 272 (4.8) \\ Ward & 10 \ 641 (47.9) & 4007 (55.4) & 2502 (43.8) \\ Level 1 & 2749 (12.4) & 1056 (14.6) & 622 (10.9) \\ Level 2 \ or \ enhanced \ care & 7913 (35.6) & 2060 (28.5) & 2354 (41.2) \\ Level 3 & 915 (4.1) & 107 (1.5) & 235 (4.1) \\ \end{array} $		X-major	8062 (36.3)	4030 (55.7)	401 (7.0)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	perations in preceding month,	1		7018 (97.1)	5441 (95.2)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	menualing maex procedure	2 or more	802 (4 0)	211 (2.0)	272 (1 8)
Level 1 2749 (12.4) 1056 (14.6) 622 (10.9) Level 2 or enhanced care 7913 (35.6) 2060 (28.5) 2354 (41.2) Level 3 915 (4.1) 107 (1.5) 235 (4.1) reoperative physiological and biochemical variables 140 (138–141) 140 (138–142) 140 (138–141)				. ,	· · ·
Level 1 2749 (12.4) 1056 (14.6) 622 (10.9) Level 2 or enhanced care 7913 (35.6) 2060 (28.5) 2354 (41.2) Level 3 915 (4.1) 107 (1.5) 235 (4.1) reoperative physiological and biochemical variables 140 (138–141) 140 (138–142) 140 (138–141)	lanned postoperative level of care	Ward	10 641 (47.9)		2502 (43.8)
Level 2 or enhanced care 7913 (35.6) 2060 (28.5) 2354 (41.2) Level 3 915 (4.1) 107 (1.5) 235 (4.1) reoperative physiological and biochemical variables 140 (138–141) 140 (138–142) 140 (138–141)		Level 1	2749 (12.4)	1056 (14.6)	622 (10.9)
Level 3 915 (4.1) 107 (1.5) 235 (4.1) reoperative physiological and biochemical variables 140 (138–141) 140 (138–142) 140 (138–141)				· · ·	
reoperative physiological and biochemical variables erum sodium (mmol L^{-1}) 140 (138–141) 140 (138–142) 140 (138–141)					
erum sodium (mmol L^{-1}) 140 (138–141) 140 (138–142) 140 (138–141)	reoperative physiological and biochomic		915 (4.1)	107 (1.5)	235 (4.1)
		ui vullubles	110 (120 111)	110 (120 110)	110 (120 111)
erum potassium (mmol L^{-4})4.4 (4.1–4.6)4.4 (4.1–4.6)4.4 (4.1–4.6)			· · · ·	· · ·	· · ·
	erum notassium (mmol L ⁻¹)		4.4 (4.1–4.6)	4.4 (4.1–4.6)	4.4 (4.1–4.6)

Factor	Class	Main cohort (N=22218)	Colorectal surgery subgroup (N=7230)	Multispecialty subgroup (N=5713)
Serum creatinine (µmol L ⁻¹)		75 (64–89)	75 (65–88)	77 (66–92)
Serum white cell count (10^{9} L ⁻¹)		7.2 (5.9–8.8)	7.2 (6-8.7)	7.2 (5.9–8.7)
Serum haemoglobin (g dl^{-1})		13.3 (12.1–14.4)	13.1 (11.7–14.3)	13.5 (12.3–14.6)
HR (beats min ^{-1})		76 (67–85)	76 (67–85)	76 (67–85)
Systolic BP (mm Hg)		135 (122–148)	136 (123–148)	136 (124–150)
Peripheral oxygen saturation (%) Intraoperative factors		98 (96–99)	98 (96–99)	97 (96–98)
Operative approach	Laparoscopic	9892 (44.5)	5372 (74.3)	1710 (30.0)
operative approach	Open	10 238 (46.1)	1698 (23.5)	2744 (48.0)
	Robotic	1130 (5.1)	158 (2.2)	792 (13.9)
	Thoracoscopic	958 (4.3)	2 (0.03)	467 (8.2)
Intraoperative blood loss*	<100 ml	7041 (31.7)	2768 (38.3)	1612 (28.2)
introperative blood lobb	100-1000	7157 (32.2)	2274 (31.5)	1931 (33.8)
	>1000	2334 (10.5)	312 (4.3)	789 (13.8)
	Recorded missing	5686 (25.6)	1876 (25.9)	1381 (24.2)
Duration of surgery	<2 h	1587 (7.1)	259 (3.6)	290 (5.1)
Juration of surgery	<2 II 2–3 h	()	. ,	· · ·
		5537 (24.9)	1934 (26.7)	1337 (23.4)
Deviewerting weeks and wetring	>3 h	15 094 (67.9)	5037 (69.7)	4086 (71.5)
Perioperative processes and metrics		14 051 (62 0)		2225 (50.2)
ER protocol used		14 051 (63.2)	5843 (80.8)	3325 (58.2)
Preoperative bowel prep		6634 (29.9)	4312 (59.6)	998 (17.5)
Preoperative carbohydrate loading	Yes	10 765 (48.5)	5216 (72.1)	2417 (42.3)
	Unknown	3221 (14.5)	796 (11.0)	856 (15.0)
Epidural catheter sited		4476 (20.1)	1233 (17.1)	1319 (23.1)
Intrathecal anaesthesia		7595 (34.2)	3724 (51.5)	1673 (29.3)
Regional block used		3078 (13.9)	878 (12.1)	980 (17.2)
Intraoperative depth of anaesthesia monitoring		5997 (27.0)	1840 (25.4)	1498 (26.2)
Intraoperative peripheral nerve stimulator use		7094 (31.9)	2793 (38.6)	1702 (29.8)
Intraoperative temperature probe		16 167 (72.8)	5399 (74.7)	4184 (73.2)
Severity of postoperative pain (in recovery)	None	9206 (41.4)	3190 (44.1)	2369 (41.5)
<i></i>	Mild	4894 (22.0)	1579 (21.8)	1265 (22.1)
	Moderate	4350 (19.6)	1416 (19.6)	1138 (19.9)
	Severe	2309 (10.4)	657 (9.1)	581 (10.2)
	Unable to assess	1459 (6.6)	388 (5.4)	360 (6.3)
Core temperature >36°C immediately postoperatively		19 716 (88.7)	6399 (88.5)	5043 (88.3)
Abdominal drain(s) sited		9257 (41.7)	2828 (39.1)	2869 (50.2)
Nasogastric tube postoperatively		3252 (14.6)	622 (8.6)	938 (16.4)
Drinking, eating, mobilising, and i.v	fluid cessation within 24	h of surgery		. ,
DrEaM		13 112 (59.0)	4341 (60.0)	3421 (59.9)
DrEaM+		10 348 (46.6)	3367 (46.6)	2650 (46.4)
Drank		19 487 (87.7)	6573 (90.9)	5069 (88.7)
Ate		15 302 (68.9)	4888 (67.6)	4010 (70.2)
Mobilised out of bed		17 207 (77.4)	5925 (82.0)	4349 (76.1)
ntravenous fluids discontinued		13 411 (60.4)	4422 (61.2)	3342 (58.5)

ASA, American Society of Anesthesiologists; AXA, AXA health classification; DrEaM, drinking, eating, and mobilising; GI, gastrointestinal; NYHA, New York Heart Association.

POSSUM (physiological and operative severity score for the enumeration of mortality) classification.

modelling process was repeated in the multispecialty subgroup to assess generalisability beyond the four included colorectal procedures. Two additional models were constructed in the colorectal subgroup to sequentially test the association of DrEaMing+ with prolonged LOS, and component DrEaMing+ processes (drinking, eating, mobilising, and cessation of i.v. fluids) with prolonged LOS.

Analysis and dataset management were performed in Stata®15 (StataCorp LP, College Station, TX, USA).

Results

The exploratory cohort comprised 22 218 participant records, submitted by 135 hospitals. Of these, 7230 were included in colorectal and 5713 in multispecialty subgroup analyses (Supplementary Fig. S1). We excluded 180 (0.7%) records of participants who died in hospital. Sensitivity analyses indicated lower compliance with DrEaMing, and longer LOS in those who died and those who underwent excluded procedures (Supplementary Table S4). In contrast, compliance with

Table 2 Independent predictors of DrEaMing (drinking, eating, and mobilising) 24 h after surgery in the exploratory cohort, identified using single level and multilevel multivariable logistic regression models. Median OR for multilevel model 0.79 (95% CI 0.68–0.90).

	Single le	vel model	Р	Multilev	el model	Р
	OR	95% CI		OR	95% CI	
Case mix descriptors						
Age (yr)	1.00	1.00-1.01	0.10	1.00	1.00-1.00	0.57
Sex						
Male Female	1.06 Ref	0.99-1.14	0.08	1.08 Ref	1.01-1.17	0.03
ASA physical status	Kei			Kei		
1 or 2	Ref			Ref		
3	0.89	0.83-0.97	0.01	0.88	0.81-0.96	0.00
4 or 5	0.82	0.60-1.11	0.19	0.86	0.62-1.18	0.35
Body mass index (BMI), kg m ^{-2} Serum sodium (mmol L ^{-1})	1.00 1.01	1.00-1.00 0.99-1.02	0.19 0.34	1.00 1.01	1.00 - 1.00 1.00 - 1.02	0.37 0.22
Serum potassium (mmol L^{-1})	1.00	1.00-1.00	0.04	1.01	1.00-1.02	0.22
Serum creatinine (μ mol L ⁻¹)*	1.10	0.91-1.33	0.32	1.15	0.94-1.40	0.17
Serum white cell count (10 ⁹ L ⁻¹)	1.00	0.99-1.01	0.69	1.00	0.99-1.01	0.85
Serum haemoglobin (g dl ⁻¹)	1.03	1.01-1.05	0.00	1.03	1.01-1.05	0.01
Heart rate (beats min^{-1})	1.00	1.00-1.00	0.11	1.00	1.00-1.00	0.10
Systolic pressure (mm Hg)	1.00	1.00-1.00	0.00	1.00	1.00-1.01	0.00
Peripheral O ₂ saturation (%) Malignancy [†]	0.98	0.96-1.00	0.05	0.99	0.96-1.01	0.25
None	Ref			Ref		
Primary only	0.98	0.91-1.07	0.67	1.06	0.97-1.16	0.17
Metastatic	1.11	1.00-1.24	0.06	1.21	1.07-1.36	0.00
Operative urgency						
Elective	Ref	0.02 1.15	0 5 9	1.06	0.02 1.20	0.40
Expedited ECG abnormalities [†]	1.03	0.93-1.15	0.58	1.06	0.93-1.20	0.40
None	Ref					
AF 60–90	0.98	0.83-1.16	0.83	1.00	0.84-1.20	1.00
AF >90/other	0.96	0.87-1.06	0.45	1.03	0.93-1.15	0.58
Not done	0.98	0.87-1.11	0.80	1.01	0.89-1.16	0.83
Cardiac signs [†]	Def					
No failure Antihypertensive, diuretic, digoxin	Ref 1.01	0.93-1.09	0.82	1.02	0.94-1.11	0.65
Peripheral oedema	1.03	0.83-1.29	0.78	1.02	0.82-1.31	0.05
Dyspnoea (respiratory signs)†						
None	Ref			Ref		
On exertion	0.83	0.75-0.92	0.00	0.86	0.77-0.96	0.01
Limiting exertion	0.91	0.75-1.11	0.35	0.90	0.73-1.10	0.31
NYHA I	Ref					Ref
I II	0.95	0.86-1.04	0.28	0.88	0.79-0.98	0.02
III or IV	0.76	0.62-0.93	0.01	0.77	0.62-0.96	0.02
Pneumonia in preceding month						
No	Ref					Ref
Yes Corebrandor diagona	0.93	0.78-1.09	0.37	0.91	0.76-1.09	0.30
Cerebrovascular disease No	Ref			Ref		
Yes	1.05	0.90-1.22	0.57	1.03	0.87-1.21	0.74
Dementia	2					
No	Ref			Ref		
Yes	0.81	0.56-1.17	0.26	0.85	0.58-1.24	0.39
Diabetes mellitus None	Def			Def		
Yes	Ref 1.03	0.94-1.14	0.49	Ref 0.98	0.00 1.00	0.65
Liver disease	1.05	0.24-1.14	0.49	0.30	0.88-1.08	0.05
No	Ref			Ref		
Yes	1.41	1.04-1.90	0.03	1.53	1.11-2.10	0.01
Smoking history	-					
Never	Ref	0.07	o o=	Ref	0.00 1.55	<u> </u>
Quit >6 months previous	0.93	0.87-1.00	0.05	0.95	0.88-1.02	0.18
Current or quit <6 months previous Unknown	0.96 1.01	0.87—1.05 0.86—1.18	0.39 0.94	0.97 0.99	0.88-1.07 0.84-1.18	0.56 0.92
Temporal factors	1.01	0.00-1.10	0.94	0.99	0.07-1.10	0.92
Day surgery was performed						
Sunday	0.84	0.42-1.69	0.62	0.73	0.36-1.47	0.37
						Continued

Table 2 Continued

	Single level	model	Р	Multilev	el model	Р
	OR	95% CI		OR	95% CI	
Monday	0.91	0.83-1.00	0.05	0.92	0.83-1.01	0.08
Tuesday	Ref			Ref		
Wednesday	1.00	0.91-1.09	0.98	1.00	0.91-1.10	0.9
Thursday	0.90	0.82-0.99	0.02	0.93	0.84-1.03	0.1
Friday	0.86	0.77-0.95	0.01	0.89	0.79-1.00	0.0
Saturday	0.72	0.42-1.23	0.23	0.67	0.38-1.17	0.1
ear index procedure was performed						
	1 1 4		0.00	1.10	0.16 0.16	0.0
2016	1.14	0.17-7.57	0.89	1.16	0.16-8.46	0.8
2017	0.71	0.61-0.82	0.00	0.76	0.64-0.89	0.0
2018	0.82	0.71-0.94	0.01	0.88	0.75-1.02	0.1
2019	0.89		0.12	0.92		0.2
		0.78-1.03	0.12		0.79-1.07	0.2
2020	Ref			Ref		
erioperative processes and metrics						
urgical specialty						
5 1 1	D-f			Def		
Colorectal	Ref			Ref		
Abdominal (other)	1.35	1.12-1.62	0.00	1.24	1.02-1.51	0.0
Burns and plastics	5.70	4.29-7.58	0.00	3.41	2.44-4.77	0.0
-	2.96			2.76		0.0
Gynaecology		2.11-4.14	0.00		1.92-3.97	
Head and neck	1.00	0.79-1.26	1.00	0.59	0.45-0.77	0.0
Hepatobiliary	2.22	1.93-2.55	0.00	2.09	1.75-2.51	0.0
Orthopaedics	1.27	1.06-1.52	0.01	1.83	1.44-2.33	0.0
•						
Spinal	1.90	1.51-2.40	0.00	2.77	2.02-3.80	0.0
Thoracics	5.10	4.08-6.37	0.00	6.18	4.80-7.95	0.0
Upper GI	0.56	0.46-0.68	0.00	0.52	0.42-0.65	0.0
Urology	2.25	1.99-2.53	0.00	2.23	1.96-2.55	0.0
Vascular	2.14	1.47-3.11	0.00	1.54	1.04-2.29	0.0
Operative approach						
	D-f			D-f		
Open	Ref.			Ref		
Laparoscopic	1.44	1.34-1.56	0.00	1.45	1.34-1.58	0.0
Robotic	1.02	0.87-1.20	0.78	1.18	0.99-1.41	0.0
Jumber of preceding operations during index						0.0
				D (
None	Ref.			Ref		
≥1	0.80	0.68-0.94	0.01	0.87	0.73-1.03	0.1
XA operative severity code						
. ,	Dof			Def		
Complex/major	Ref.			Ref		
X-major	0.95	0.88-1.02	0.17	0.98	0.91-1.06	0.6
nhanced recovery protocol used						
No	Ref.			Ref		
		4 00 4 11	0.00		1 00 1 00	
Yes	1.31	1.22-1.41	0.00	1.18	1.09-1.29	0.0
reoperative bowel preparation administered						
No	Ref.			Ref		
		0.00 1.04	0.01		0.05 4.04	
Yes	0.96	0.89-1.04	0.31	0.92	0.85-1.01	0.0
reoperative carbohydrate loading						
No	Ref.			Ref		
		106 105	0.00		0 0 / 1 01	~ ~
Yes	1.15	1.06-1.25	0.00	0.92	0.84-1.01	0.0
Unknown	0.99	0.89-1.09	0.78	0.86	0.77-0.96	0.0
erioperative epidural analgesia						
	Ref.			Pof		
No				Ref		_
Yes	0.82	0.75-0.89	0.00	0.67	0.61-0.75	0.0
ntrathecal anaesthesia/analgesia						
No	Ref.			Ref		
Yes	1.08	1.00-1.16	0.04	1.06	0.97-1.15	0.2
egional anaesthesia/analgesia						
No	Ref.			Ref		
			a			
Yes	1.00	0.91-1.11	0.97	0.94	0.84-1.04	0.24
ntraoperative depth of anaesthesia monitorir	ng					
No	Ref.			Ref		
Yes	0.92	0.85-0.99	0.02	1.02	0.94-1.12	0.6
ntraoperative neuromuscular monitoring						
	Pof			Dof		
No	Ref.			Ref		
Yes	1.03	0.96-1.10	0.48	1.06	0.98-1.15	0.1
ntraoperative temperature probe used						
	Dof			Def		
No	Ref.			Ref		
Yes	1.08	0.98-1.19	0.11	1.03	0.93-1.15	0.5
Juration (h)						
Duration (h)	D -f					
<2	Ref.			Ref		
	Ref. 0.72	0.62-0.84	0.00	Ref 0.73	0.62-0.85	0.00

Tab	le 2	Contin	ued
1 ub		Gommi	aca

	Single lev	vel model	Р	Multileve	el model	Р
	OR	95% CI		OR	95% CI	
>3	0.51	0.44-0.60	0.00	0.52	0.44-0.61	0.00
Blood loss (ml)						
<500	Ref.			Ref		
500-1000	0.77	0.71-0.83	0.00	0.77	0.71-0.85	0.00
>1000	0.54	0.48-0.61	0.00	0.56	0.49-0.63	0.00
Missing data	0.80	0.73-0.87	0.00	0.77	0.70-0.85	0.00
Postoperative level of care						
Ward	Ref.			Ref		
1	0.66	0.60-0.73	0.00	0.70	0.62-0.79	0.00
1.5 or 2	0.50	0.47-0.54	0.00	0.48	0.44-0.53	0.00
3	0.31	0.26-0.37	0.00	0.26	0.21-0.31	0.00
Severity of immediate postoperativ	ve pain					
None	Ref.			Ref		
Mild	0.95	0.88-1.03	0.23	0.95	0.87-1.03	0.22
Moderate	0.89	0.82-0.97	0.01	0.90	0.82-0.99	0.03
Severe	0.69	0.62-0.77	0.00	0.72	0.64-0.80	0.00
Unable to assess	0.60	0.52-0.69	0.00	0.70	0.60-0.81	0.00
Core temperature >36°C in recover	ry room					
No	Ref.			Ref		
Yes	0.90	0.84-0.97	0.01	0.97	0.89-1.05	0.44
Intra-abdominal drain in place pos	stoperatively					
No	Ref.			Ref		
Yes	0.66	0.62-0.71	0.00	0.70	0.64-0.75	0.00
Nasogastric tube in place postoper	atively					
No	Ref.			Ref		
Yes	0.33	0.29-0.36	0.00	0.32	0.29-0.36	0.00

ASA, American Society of Anesthesiologists; AXA, AXA health classification; CI, confidence interval; GI, gastrointestinal; NYHA, New York Heart Association; OR, odds ratio.

* Quadratic transformation.

 † POSSUM (physiological and operative severity score for the enumeration of mortality) classification.

DrEaMing was near-universal in patients discharged within 1 day of surgery. Overall, missingness was extremely low (Supplementary Table S3).

Exploratory cohort

Median age was 66 yr, 56% were male, and 29% ASA \geq 3 (Table 1). Colorectal procedures were most numerous (49.5%) (Table 1). Median postoperative LOS was 6 days (inter-quartile range [IQR] 4–9) overall, but varied by surgical specialty, ranging from 3 days (IQR 2–4) after gynaecological surgery, to 8 days (IQR 5–12) after upper gastrointestinal (GI) and head and neck procedures (Supplementary Table S5).

Compliance with DrEaMing was 13 112 (59%) patients within 24 h of surgery overall (Table 1). Compliance was highest for drinking (19 487, [88%] patients) (Table 1). Regression modelling identified several fixed and potentially modifiable factors that predicted DrEaMing at 24 h (Table 2). Advanced functional limitation, and head and neck and upper GI surgery (despite exclusions) predicted failure. Predictors of success included delivery of other ERP components (Table 2), higher preoperative haemoglobin levels, less intraoperative bleeding, and better perioperative pain control; and successive calendar years since 2017. DrEaMing was achieved more often after surgery on Tuesday and Wednesday, compared with the rest of the week, but there was insufficient statistical evidence to be certain about day of the week differences.

Without adjustment for confounders, DrEaMing patients had a 3 day shorter median LOS {5 days (95% confidence interval

[CI] 5–5 days)} than those who did not DrEaM (8 days [95% CI 8–8 days]). DrEaMing+, and each individual component, were also associated with shorter median LOS, with 95% CIs indicating reductions of between 2 and 5 days (Supplementary Table S6).

Overall, 5638 patients (25.4%) developed at least one major postoperative complication during their admission, but this varied by delivery of DrEaMing: the incidence of one or more major complications was 37% among patients who failed to DrEaM and 17% in those who achieved DrEaMing (Supplementary Table S7). Major pulmonary (3.7 vs 1.9), cardiovascular (4.8 vs 1.9), and GI (20.7 vs 6.3) complications were more common in those who failed to DrEaM than in those who DrEaMed (Supplementary Table S7).

Colorectal subgroup

Eligible records were submitted by 113 hospitals, with a median of 55 records per hospital. Patient characteristics were generally similar to the main cohort (Table 1), with a few notable exceptions: colorectal surgery tended to be more complex (56% complex major, in comparison with 36%), was more frequently for cancer resection (83% vs 69%), and enhanced recovery protocols were used with greater consistency (80% vs 63%) overall.

In total 4341 (60%) patients DrEaMed within 24 h of surgery (Table 1) but the degree of variation between hospitals was substantial (median 63%, IQR 37–73%, range 0–100%; Supplementary Fig. S2). As with the main exploratory cohort,

Table 3 Predictors of prolonged postoperative length of stay after colorectal surgery: multilevel analysis testing DrEaMing (drinking, eating, and mobilising) as the variable of interest (median odds ratio 0.56 [0.45–0.71] P<0.001). AF, atrial fibril-lation; CI, confidence interval.

Variable	Odds ratio	95% CI	Р
Variable of interest			
DrEaMing status at 24 h			
Delivered	0.51	0.43-0.59	0.00
Not delivered	Ref		
Case-mix variables	d hie chemi		
Preoperative physiological and Age (yr)	1.02	1.01–1.03	0.00
Body mass index (BMI),	1.02	1.00-1.01	0.00
kg m ⁻²	1.01	1.00 1.01	0.05
Serum [sodium]	0.99	0.97-1.02	0.52
Serum [potassium]	0.96	0.80-1.14	0.71
Serum [creatinine]	0.64	0.40-1.02	0.06
Serum white cell count	1.03	0.99-1.06	0.10
Serum [haemoglobin] HR	0.99 1.00	0.95-1.04 1.00-1.01	0.69 0.15
Systolic BP	1.00	1.00 - 1.01 1.00 - 1.00	0.13
Oxygen saturations	0.96	0.92-1.01	0.14
Sex			
Male	1.38	1.17-1.63	0.00
Female	Ref		
ASA physical status	Dof		
1	Ref 0.81	0.62 1.04	0.10
2	1.10	0.62—1.04 0.82—1.49	0.10
4 or 5	1.56	0.79-3.07	0.20
Malignancy*			
No solid tumour	Ref		
Local disease	0.99	0.80-1.22	0.92
Nodal or metastatic spread	1.03	0.78–1.36	0.82
Preoperative ECG*	Ref		
No abnormality AF: rate 60–90 beats min ⁻¹	1.00	0.72-1.40	0.99
AF >90/other abnormality	0.90	0.72 1.40	0.32
ECG was not performed	1.13	0.83-1.54	0.44
Cardiac findings*			
No failure	Ref		
Diuretic/antihypertensive	1.09	0.91-1.30	0.33
Peripheral oedema/	1.14	0.72-1.80	0.58
cardiomegaly Dyspnoea*			
None			
On exertion	0.95	0.76-1.19	0.65
Limiting exertion/at rest	0.92	0.61-1.39	0.70
NYHA class			
I	Ref	0.00 4.07	0.05
II III or IV	1.11	0.89-1.37	0.35
Cerebrovascular disease	0.98	0.63–1.52	0.93
History	1.32	0.95-1.82	0.09
No history	Ref		
Dementia			
History	1.66	0.76-3.60	0.20
No history	Ref		
Diabetes mellitus None	Ref		
Non-insulin-dependent	1.11	0.89-1.39	0.34
Insulin-dependent	0.92	0.62-1.35	0.66
Liver disease			
History	1.89	0.93-3.83	0.08
No history	Ref		
Smoking history	D -f		
Never smoked Unknown	Ref 1.18	0.80-1.76	0.40
Chikilowii	1.10	0.00 1.70	0.10
		Co	ntinued

Table 3 Continued

Variable	Odds ratio	95% CI	Р
Quit >6 months ago	1.08	0.92-1.26	0.37
Quit <6 months ago	1.18	0.81-1.72	0.39
Current smoker	1.21	0.93–1.58	0.16
Operative urgency	Def		
Elective Expedited	Ref 0.89	0.69-1.14	0.35
Major postoperative complica		0.09-1.14	0.55
>1	12.59	10.78-14.69	0.00
None	Ref		
Perioperative processes and n	netrics		
Operation			
Anterior resection	Ref	0.00 1.00	0.00
Right hemicolectomy	1.09 0.89	0.90-1.33 0.68-1.16	0.36 0.38
Sigmoid colectomy Left hemicolectomy	1.28	0.88-1.18	0.38
Number of preceding operatio			
None	Ref		
≥ 1	1.23	0.82-1.84	0.33
Mode of surgery			
Open	Ref		
Laparoscopic/robotic	0.59	0.50–0.69	0.00
Enhanced recovery protocol Used	1.04	0.84-1.28	0.73
Not used	Ref	0.01 1.20	5.75
Preoperative bowel preparatio		ered	
Yes	0.95	0.80-1.13	0.55
None	Ref		
Preoperative carbohydrate ad			
Yes	0.98	0.79-1.21	0.84
Unknown	1.23 Pof	0.92–1.63	0.16
None Perioperative epidural analges	Ref		
Yes	1.45	1.16-1.82	0.00
None	Ref		
Intrathecal analgesia			
Yes	0.96	0.81-1.14	0.64
None	Ref		
Regional anaesthesia/analges Yes	1a 0.94	0.74-1.18	0.60
None	Ref	0.74-1.18	0.00
Intraoperative depth of anaes		toring	
Used	0.93	0.77-1.12	0.46
Not used	Ref		
Intraoperative neuromuscular			
Used	0.93 Def	0.79-1.09	0.35
Not used	Ref		
Intraoperative temperature pr Used	0.93	0.77-1.11	0.40
Not used	Ref	2.,, 1.11	5.10
Duration of surgery			
<2 hours	Ref		
2–3 hours	0.78	0.51-1.18	0.24
>3 hours	0.98	0.65-1.49	0.94
Postoperative level of care 0	Ref		
1	1.09	0 84-1 42	0.50
1 1.5 or 2	1.09	0.84-1.42 1.02-1.50	0.00
3	1.55	0.99-2.43	0.06
Severity of postoperative pain			
None	Ref		
	1.15	0.95-1.39	0.14
Mild			0.66
Mild Moderate	1.05	0.86-1.28	
Mild Moderate Severe	1.36	1.05-1.77	0.02
Mild Moderate Severe Unable to assess	1.36 1.03	1.05–1.77 0.74–1.44	
Mild Moderate Severe Unable to assess Core temperature >36°C in ree	1.36 1.03 covery room	1.05–1.77 0.74–1.44	0.02 0.84
Mild Moderate Severe Unable to assess Core temperature >36°C in ree Yes	1.36 1.03 covery room 1.19	1.05–1.77 0.74–1.44	0.02
Mild Moderate Severe Unable to assess Core temperature >36°C in ree	1.36 1.03 covery room	1.05–1.77 0.74–1.44	0.02 0.84

Variable	Odds ra	tio 95% CI	Р
Intra-abdominal drain	in place postope	ratively	
Yes	1.43	1.21–1.70	0.00
None	Ref		
Nasogastric tube in pl	ace postoperative	ely	
Yes	1.63	1.27-2.09	0.00
None	Ref		
Day of the week surge	ery was performe	d	
Monday	1.05	0.84-1.31	0.66
Tuesday	Ref		
Wednesday	1.01	0.82-1.25	0.91
Thursday	1.03	0.83-1.27	0.82
Friday	0.86	0.67-1.11	0.26
Saturday	1.12	0.24-5.33	0.89
Sunday	1.24	0.14-11.35	0.85

^{*} POSSUM (physiological and operative severity score for the enumeration of mortality) or combined POSSUM categories.

Table 4 Independent predictors of prolonged postoperative length of stay—multilevel analysis in the colorectal cohort testing DrEaMing+ (DrEaMing plus the cessation of i.v. fluid administration) component variables (median odds ratio 0.45 [0.35–0.56]). Covariates were modelled to adjust for confounding, but their estimates are not reported here. CI, confidence interval; DrEaMing, drinking, eating, and mobilising.

Processes delivered 24 h after surgery	Odds ratio	95% CI	Р
Drinking	0.66	0.52-0.84	<0.001
Not drinking	Ref.		
Eaten	0.72	0.54-0.97	0.03
Not eaten	Ref.		
Mobilised	0.66	0.53-0.83	< 0.001
Not mobilised	Ref.		
I.V. fluids discontinued	0.77	0.66-0.91	< 0.001
I.V. fluids not discontinued	Ref.		

compliance was highest with drinking (6573 [91%] patients; Table 1).

Median postoperative LOS in the colorectal subgroup was 6 (IQR 4-9) days overall, with similar distributions by individual operative procedure (Supplementary Table S8). Prolonged LOS was therefore defined as postoperative LOS exceeding 8 days after right or left hemicolectomy with anastomosis, or exceeding 10 days after anterior resection or sigmoid colectomy. LOS varied markedly between hospitals (Supplementary Fig. S3). Delivery of DrEaMing was associated with a 2-day shorter median LOS (5 days [95% CI 5-5 days]), compared with failure (7 days [95% CI 7-7 days]) (Supplementary Table S9). DrEaMing+, and each individual component, were also associated with shorter median LOS, with 95% CIs indicating reductions of between 2 and 3 days (Supplementary Table S9). Major postoperative complications were more common in patients who did not DrEaM at 24 h (32%) compared with those who did (17%) (Supplementary Table S7).

In multilevel analysis, delivery of DrEaMing was associated with substantially reduced odds of prolonged LOS (OR 0.51

[95% CI 0.43–0.59]), controlling for measured confounders (Table 3). Median odds ratio (MOR) was 0.56 (0.45–0.71), indicating substantial influence of unmeasured hospital-level effects on the outcome. DrEaMing+ was associated with similar magnitude odds reduction (OR 0.54 [0.46–0.63]), and the component variables with ORs of between 0.66 and 0.77 (Table 4).

Stratified by DrEaMing delivery, the highest performing quintile of hospitals delivered DrEaMing in >80% of colorectal surgical patients, contrasting with delivery to fewer than 33% in the lowest performing hospitals. Postoperative LOS was significantly shorter at the highest quintile hospitals (median 5 days [95% CI 5–6 days]) than the lowest (median 7 days [95% CI 6–7 days]), Kruskall–Wallis P<0.001 (Fig 1). Although a 'dose response' was not evident across the quintiles, these observations suggest that consistent process delivery was associated with shorter LOS. Contrasting with variation in LOS, the incidence of major postoperative complications varied by only 3% between quintiles, supporting our multilevel findings of an association between DrEaMing and shorter LOS, and indicating that complications were not the primary determinant of LOS (Fig 1).

Multispecialty subgroup

This subgroup comprised 5713 patients undergoing thoracic, urological, hepatobiliary, orthopaedic, and colorectal operations (Supplementary Table S8). Case volume ranged from 758 (thoracoscopic lobectomy) to 401 (right hemicolectomy with ileostomy). In contrast with the colorectal cohort, patients were more comorbid (31% ASA physical status >2) but underwent proportionately less invasive, open surgery. Median postoperative LOS ranged from 2 days after radical prostatectomy to 10 days after Whipple's procedure, with prolonged LOS ranging from >4 days to >15 days, respectively (Supplementary Table S9). Whereas these patients were less frequently enrolled onto ERPs than colorectal cohort patients, the proportion of DrEaMing patients was identical between subgroups (Table 1). Repeating the process of multilevel multiple logistic regression on prolonged postoperative LOS in this cohort yielded a similar odds reduction associated with DrEaMing 24 h after surgery to that observed in the colorectal cohort (OR 0.53 [95% CI: 0.45-0.63], P<0.001; Supplementary Table S10).

Discussion

This study is the first to evaluate the association between DrEaMing compliance and postoperative LOS after major surgery in a large multicentre cohort. We report five key findings. First, delivery of DrEaMing and its component variables were each associated with an approximately halved likelihood of prolonged LOS, both after colorectal surgery and after a representative selection of thoracic, orthopaedic, hepatobiliary, and urological procedures. Second, of the case-mix and process factors that predicted whether patients achieved DrEaMing, all except surgical specialty are potentially modifiable. Third, only the development of a major postoperative complication carried a greater risk of prolonged LOS than failure to deliver DrEaMing. Fourth, at hospital level, major complications was not the primary determinant of LOS after colorectal surgery, instead consistent delivery of DrEaMing




Fig 1. Quintile analysis, in which hospitals were stratified on the distribution of the proportion of patients DrEaMing (drinking, eating, and mobilising) per hospital (q20: 33%, q40: 45%, q60: 67%, q80: 81%). (a) Incidence of major postoperative morbidity (Clavien-Dindo \geq Grade II), range 21–24% at Q5 and Q3 hospitals, respectively (P=0.21). (b) Postoperative median length of stay, 7 (5–9) days at Q1 hospitals and 5 (4–8) days at Q5 hospitals (P<0.001, Kruskall–Wallis).

was associated with significantly shorter LOS. Finally, we note that epidural catheters, nasogastric tubes, abdominal drains, and experiencing severe pain immediately after surgery were each independently associated both with failure to DrEaM and prolonged LOS.

For improvement endeavours to be effective, it is important to understand the level of compliance with processes of interest, and the barriers to and facilitators of this compliance. The challenges of implementation and maintenance of and adherence to ERPs are well documented, despite national programmes to support their delivery.⁴.²⁶ Previous analysis of the PQIP cohort by our group has found consistently high compliance for some enhanced recovery elements, including preoperative assessment, perioperative antibiotic prophylaxis, and temperature management.²⁷ Monitoring, rather than high-intensity improvement endeavours, is appropriate for this group of 'normalised' processes. Technical interventions, most notably minimal access approaches, and avoidance of nasogastric tubes and abdominal drains, have proved more resistant to change at hospital level.²⁷.²⁸ These types of process require detailed investigation of local case mix, infrastructure, attitudes, and behaviours in order to understand variation and challenge dogmatism, where appropriate. The evidence for processes such as goal-directed fluid optimisation, bowel preparation, and carbohydrate loading remains contested.⁷.²⁹

It could be argued that system change should not be attempted until evidence from a randomised trial is available, but in contrast with the processes discussed above, the DrEaMing bundle is an ideal target for locally driven quality improvement: its rationale is simple (supporting its inclusion in a care bundle); there is variation in compliance rates between hospitals; but also evidence that improvement, to achieve consistent delivery of the bundle (to at least 80% of patients), is achievable.¹⁴ Furthermore, since ER programmes are associated with cost savings for healthcare providers,⁴ streamlining complex ERPs to re-prioritising DrEaMing may deliver financial incentives. In recognition of its clinical, patient-centric, and organisational importance, subsequent to our analyses, NHS England has prioritised DrEaMing as a core clinical priority area (commissioning for quality and innovation, CQUIN), in which improvement is expected in 2022/23.³² Targeted initiatives to support DrEaMing implementation will need to reach beyond the clinical domain, to involve organisational culture (specifically staff attitudes and behaviours), and structural factors (including finances and staffing), since these have been shown to influence the success of change programmes.^{11,33}

Whether DrEaMing is a process or an outcome is a matter for debate. Our assertion is that it is both. DrEaMing provides a useful target around which further process evaluation can be based-for example, ensuring that all of the required actions to support drinking within 24 h have been delivered—such as clear instructions from the surgical/perioperative team to the ward team, provision of oral fluids, adequate analgesia and antiemesis, and so on. To that end, we can map the processes required to achieve each element of DrEaMing and hypothesise about reasons for success or failure, which would explain between-hospital (rather than between-patient) variation. For example, our weak signal (wide CIs around point estimates) that DrEaMing may be less frequently delivered over weekends, has face validity because processes such as mobilisation may be impeded by workforce constraints (e.g. access to physiotherapists). Opportunities for improvement can therefore also be developed—for example, alternative approaches such as nurseor therapy assistant-led interventions may provide solutions to workforce challenges.³⁴ In hospitals with reliable processes of care and a culture which promotes DrEaMing, failure to achieve the process/early outcome of DrEaMing may highlight patients who require more attention from healthcare staff, as they are at higher risk of later complications and extended LOS. Although we do not assume a causal relationship between failure to DrEaM and postoperative complications, if evaluating against the Bradford Hill criteria,³⁵ there is a strong case: strength of association; consistency of findings (if considering previous data from ERPs); temporal sequence; coherence; and biological plausibility (through reduction of fluid imbalance, nutritional depletion, and the complications of immobility, including respiratory impairment).

Strengths of this study include the systematic interrogation of a perioperative dataset of case-mix, process, and outcome variables, unparalleled in its comprehensiveness. Very few records were excluded as a result of missing data items. We expect our findings to be generalisable across healthcare systems because of the diversity of the population represented by participating hospitals, the clear definitions and low complexity of the DrEaMing intervention. There are, however, limitations to these analyses: causes of failure to DrEaM, most notably where driven by local protocols, were not available for interrogation; we did not investigate causality, so, for example, the organisational infrastructure and culture that drives high compliance with the DrEaMing bundle might also be responsible for more efficient discharge from hospital after surgery; some potential confounders (including frailty and operative blood loss) were not modelled because of missingness in or absence from the dataset; findings may not be generalisable beyond the procedures and specialties assessed; and because this was a study of UK patients treated in the NHS, findings may not be generalisable to populations with lower living standards and without comprehensive healthcare coverage. Exclusion of the small number of decedents from our analysis is unlikely to have biased our findings, as a result of the low incidence of DrEaMing in these individuals and the strength of the association between major complications and prolonged LOS. We were unable to investigate associations between shorter postoperative LOS and post-discharge outcomes, and future analyses incorporating readmission, discharge destination, and mortality data are merited. Finally, important questions have been raised that this study was not designed to answer. These include identifying which patients do benefit from perioperative epidural anaesthesia, developing better approaches to postoperative analgesia, and evaluating the role of nasogastric tubes (NGTs) and abdominal drains in contemporary practice.

In summary, in this observational study, delivery of DrEaMing was associated with a 3 day reduction in LOS after a wide variety of major surgical procedures. The direction of this association was independent of confounders, including complications, with DrEaMing associated with a 41–57% reduction in the odds of prolonged hospital stay. Consistency of DrEaMing rather than incidence of complications predicted hospital-level LOS. Taken together, our analyses indicate that substantial gains may be realised, both for patients and organisations, from targeting the consistent delivery of DrEaMing. Furthermore, where early drinking, eating, mobilising, or early cessation of i.v. fluids are individually contraindicated, delivery of remaining processes may be beneficial. DrEaMing appears, therefore, to be a valuable quality metric and a DrEaMing bundle may be an important intervention in enhanced recovery programmes. An RCT would, however, be required to establish causation.

Authors' contributions

Study conception: SRM, MGM

Study design; data analysis and interpretation; manuscript first draft and revisions: CMO

Study design, manuscript first draft, and revisions: SW Study design, manuscript revisions: SRM, DM and GS Statistical overview and revisions: PM Study conduct and manuscript revisions: PM, JB, DW, AS, JW, KE, RB, CVP, JD, IL, HBC, RV, PS, MB, AV, GA, OT, MS, MGM.

Funding

The Perioperative Quality Improvement Programme (PQIP) is funded by the Royal College of Anaesthetists, UK; the University College London/University College London Hospitals Surgical Outcomes Research Centre, UK; and by the Health Foundation, UK. NIAA RCoA/BJA project grant to DMG. University College London/University College London Hospitals National Institute for Health Research (NIHR) Biomedical Research Centre to SRM and MGM. All views expressed here are those of the authors and not of the NIHR or Department of Health and Social Care.

Data availability

The data used in this study are available upon request and after approval from the Perioperative Quality Improvement Programme (PQIP) Project Team at the Royal College of Anaesthetists (https://pqip.org.uk/pages/datarequest).

Declaration of interest

All authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bja.2022.03.021.

References

- 1. Wilmore DW, Kehlet H. Management of patients in fast track surgery. BMJ 2001; 322: 473-6
- Levy N, Mills P, Mythen M. Is the pursuit of DREAMing (drinking, eating and mobilising) the ultimate goal of anaesthesia? Anaesthesia 2016; 71: 1008–12
- Lee L, Mata J, Ghitulescu GA, et al. Cost-effectiveness of enhanced recovery versus conventional perioperative management for colorectal surgery. Ann Surg 2015; 262: 1026–33
- Lee L, Li C, Landry T, et al. A systematic review of economic evaluations of enhanced recovery pathways for colorectal surgery. Ann Surg 2014; 259: 670–6
- Simpson JC, Moonesinghe SR, Grocott MPW, et al. Enhanced recovery from surgery in the UK: an audit of the enhanced recovery partnership programme 2009–2012. Br J Anaesth 2015; 115: 560–8
- 6. Varadhan KK, Neal KR, Dejong CHC, Fearon KCH, Ljungqvist O, Lobo DN. The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: a meta-analysis of randomized controlled trials. Clin Nutr 2010; 29: 434–40

- Kehlet H, Joshi GP. Enhanced recovery after surgery: current controversies and concerns. Anesth Analg 2017; 125: 2154–5
- Smith MD, Mccall J, Plank L, Herbison GP, Soop M, Nygren J. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. *Cochrane Database Syst Rev* 2014; 14: CD009161
- Toh JWT, Phan K, Ctercteko G, et al. The role of mechanical bowel preparation and oral antibiotics for left-sided laparoscopic and open elective restorative colorectal surgery with and without faecal diversion. Int J Colorectal Dis 2018; 33: 1781–91
- Abis GSA, Stockmann HBAC, Bonjer HJ, et al. Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial). Br J Surg 2019; 106: 355–63
- Aggarwal G, Peden CJ, Mohammed MA, et al. Evaluation of the collaborative use of an evidence-based care bundle in emergency laparotomy. JAMA Surg 2019; 154: 1–9
- 12. Peden CJ, Stephens T, Martin G, et al. Effectiveness of a national quality improvement programme to improve survival after emergency abdominal surgery (EPOCH): a stepped-wedge cluster randomised trial. Lancet 2019; 393: 2213–21
- Resar R, Pronovost P, Haraden C, Simmonds T, Rainey T, Nolan T. Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. Jt Comm J Qual Patient Saf 2005; 31: 243–8
- 14. Gilhooly D, Green S, McCann C, Black N, Moonesinghe S. Barriers and facilitators to the successful development, implementation and evaluation of care bundles in the acute care setting: a systematic review. *Implement* Sci 2019; 14: 1–12
- Resar R, Griffen F, Haraden C, Nolan T. Using Care Bundles to Improve Health Care Quality. IHI Innovation Series white paper. Cambridge, MA: Institute for Healthcare Improvement; 2012. Available from: www.IHI.org. [Accessed 16 April 2022]
- The CHEERS DREAM Campaign. CHEERS-DrEaM. Available from: http://cheers-dream.com. [Accessed 27 October 2020]
- 17. Loftus TJ, Stelton S, Efaw BW, Bloomstone J. A systemwide enhanced recovery program focusing on two key process steps reduces complications and readmissions in patients undergoing bowel surgery. J Healthc Qual 2017; 39: 129–35
- 18. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbrouckef JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Org 2007; 85: 867–72
- The perioperative quality improvement programme. Perioperative quality improvement programme. Available from: https:// pqip.org.uk/content/home. [Accessed 15 August 2021]
- 20. Gilhooly D, Moonesinghe SR. The perioperative quality improvement programme: improving outcomes. Br J Hosp Med 2018; 79: 117
- 21. Moonesinghe SR, McGuckin D, Martin P, et al. The Perioperative Quality Improvement Programme (PQIP Patient Study): protocol for a UK multicentre, prospective cohort study to

measure, report and improve quality and outcomes of major surgery. Published online July 12 2021. Preprint https://doi.org/10.21203/rs.3.rs-708161/v1.

- 22. Perioperative Quality Improvement Programme. PQIP Standard Operating Procedure v 2.2 (accessed 4 June 2021). Available from: https://pqip.org.uk/FilesUploaded/PQIP_ SOP_v2.2 2020-Aug-12.pdf (accessed 15 August 2021).
- 23. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–13
- 24. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery a review. JAMA Surg 2017; 152: 292–8
- 25. Sauerbrei W, Meier-Hirmer C, Benner A, Royston P. Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput Stat Data Anal 2006; 50: 3464–85
- **26.** Glorioso TJ, Grunwald GK, Ho PM, Maddox TM. Reference effect measures for quantifying, comparing and visualizing variation from random and fixed effects in nonnormal multilevel models, with applications to site variation in medical procedure use and outcomes. BMC Med Res Methodol 2018; **18**: 74
- 27. Berian JR, Ban KA, Liu JB, Ko CY, Feldman LS, Thacker JK. Adherence to enhanced recovery protocols in NSQIP and association with colectomy outcomes. Ann Surg 2019; 269: 486–93
- Moonesinghe S, Aresu G, Bampoe S, et al. Perioperative Quality Improvement Programme Annual Report 2018–19. London 2019. Available from: https://pqip.org.uk/FilesUploaded/PQIP Annual Report 2018-19.pdf. [Accessed 15 August 2021]
- Bedford J, Sahni A, Bampoe S, et al. Perioperative Quality Improvement Programme: Annual Report 2017-18 2018. Available from: https://pqip.org.uk/FilesUploaded/PQIP Annual Report 2018-19.pdf. [Accessed 15 August 2021]
- Rollins KE, Javanmard-Emamghissi H, Acheson AG, Lobo DN. The role of oral antibiotic preparation in elective colorectal surgery: a meta-analysis. Ann Surg 2019; 270: 43–58
- Pearse RM. Optimisation of peri-operative cardiovascular management to improve surgical outcome v 2.0 (accessed 4 June 2021). Available from: https://optimiseii.org/docs/ Study Protocols/OPTIMISE II Protocol v2.0 08.12.2020.pdf (accessed 15 August 2021).
- **32.** NHS England and NHS Improvement. Commissioning for quality and innovation (CQUIN): 2022/23 guidance 2022. January
- 33. Stephens TJ, Peden CJ, Pearse RM, et al. Improving care at scale: process evaluation of a multi-component quality improvement intervention to reduce mortality after emergency abdominal surgery (EPOCH trial). Implement Sci 2018; 13: 142
- 34. Jones RA, Merkle S, Ruvalcaba L, Ashton P, Bailey C, Lopez M. Nurse-led mobility program: driving a culture of early mobilization in medical-surgical nursing. J Nurs Care Qual 2020; 35: 20–6
- Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295–300

Handling editor: Paul Myles